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ABSTRACT  
Extracellular regulated kinase 5 (ERK5) signalling has been implicated in driving a number of 
cellular phenotypes including endothelial cell angiogenesis and tumour cell motility. Novel ERK5 
inhibitors were identified using high throughput screening, with a series of pyrrole-2-
carboxamides substituted at the 4-position with an aroyl group being found to exhibit IC50 values 
in the micromolar range, but having no selectivity against p38α MAP kinase. Truncation of the N-
substituent marginally enhanced potency (~ 3-fold) against ERK5, but importantly attenuated 
inhibition of p38α. Systematic variation of the substituents on the aroyl group led to the selective 
inhibitor 4-(2-bromo-6-fluorobenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide (IC50 0.82 
μM for ERK5; IC50 >120 μM for p38α). The crystal structure (PDB 5O7I) of this compound in 
complex with ERK5 has been solved. This compound was orally bioavailable and inhibited bFGF-
driven Matrigel plug angiogenesis and tumour xenograft growth. The selective ERK5 inhibitor 
described herein provides a lead for further development into a tool compound for more extensive 
studies seeking to examine the role of ERK5 signalling in cancer and other diseases. 
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INTRODUCTION  
Extracellular regulated kinase 5 (ERK5, BMK1, MAPK7) is the terminal kinase in one of the 
four major mitogen activated protein (MAP) kinase pathways [1]. MAP kinase pathways are 
central to cancer, as well as numerous other pathologies, and recent clinical success with B-RAF 
and MEK1/2 inhibitors, in melanoma in particular, has demonstrated that these kinases are 
amenable to therapeutic exploitation [2]. Correlative clinical data have implicated ERK5 as a 
potential target in a number of tumour types, including prostate and breast cancer, and mechanistic 
studies have demonstrated potential roles for ERK5 in cell migration and angiogenesis [3, 4]. 
Targeting the non-canonical MAPK pathway through inhibition of ERK5 has generated a lot of 
interest in the last decade. The oxindole-based BIX02189 (Figure 1; 1) was one of the first potent 
dual ERK5-MEK5 inhibitors reported [5]. Subsequently, pre-clinical data generated with a 
pyrimidodiazepinone small molecule inhibitor of ERK5 kinase activity (2; XMD8-92) suggested 
that perturbation of this signalling pathway can impede the growth of human tumours in vivo [6]. 
A more potent and selective ERK5 inhibitor from the pyrimidodiazepinone series, (3; AX15836) 
was subsequently disclosed as a useful tool for the study of ERK5 inhibition [7]. Recently, BAY-
885 (4) was reported as a potent ERK5 chemical probe [8]. 
 4 
Figure 1. Structures and pharmacological profiles of reported ERK5 inhibitors. 
 
A role for ERK5 in cell proliferation was first indicated by studies using dominant-negative 
ERK5 constructs that inhibited epidermal growth factor-stimulated proliferation of HeLa cells [9]. 
However, more extensive recent studies [10], using both MEK5/ERK5 inhibition and ERK5 
knockdown, do not support a role for ERK5 in cellular proliferation. In contrast, there are 
compelling data from a number of studies [11-16] demonstrating that ERK5 signalling promotes 
tumour cell migration and invasion, a property that is consistent with the clinical relationship 
between tumour ERK5 over-expression and metastatic disease. For example, in an orthotopic 
model of prostate cancer, Leung and colleagues [17] demonstrated that ERK5 promotes the 
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formation of metastases. Similarly, in an in vivo orthotopic breast cancer model, ERK5 knockdown 
resulted in a marked reduction in lymph node metastasis [18]. 
A third aspect of tumour biology that may be exploited by ERK5 inhibitors is inhibition of 
tumour angiogenesis. A substantial body of data based initially on constitutive and conditional 
knockout mouse models shows that ERK5 is required for endothelial cell survival, in particular 
maintenance of vascular integrity and endothelial cell migration. MEK5, the obligate kinase 
required for ERK5 activation, and ERK5 knockout mouse embryos die at approximately day 10.5 
from tissue failure that includes impaired cardiac development, which may result from an inability 
to permit maturation of the supporting vasculature [19, 20]. Importantly, in a conditional ERK5 
knockout adult mouse model, ERK5 depletion following Cre recombinase induction disrupts 
vascular integrity and results in death from multiple organ haemorrhage within two to four weeks 
[21], consistent with a key role for ERK5 in endothelial cell biology [22]. Further studies by 
Hayashi and colleagues [23] unequivocally link ERK5 signalling to tumour angiogenesis in two 
in vivo mouse tumour models, and in a growth-factor induced angiogenesis model. Consequently, 
treatment with an ERK5 inhibitor may be anticipated to have a therapeutic effect on tumour 
vasculature in solid cancers. 
Whilst the prototype ERK5 kinase inhibitor, XMD8-92 (2) [6], has been used to explore 
inhibition of ERK5 signalling in vivo, a recent study [24] has demonstrated that XMD8-92 (2), in 
common with some other kinase inhibitors [25], can also inhibit bromodomain (BRD) proteins, 
and that this property may underlie some of the cellular effects of the compound.  
Following a high-throughput screening campaign a pyrrole series of ERK5 inhibitors was 
identified, as exemplified by 5 [26]. Encouragingly, compound 5 passed pan-assay interference 
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(PAINS) and aggregator potential assessment [27]. The current paper describes the hit-to-lead 
development of potent ERK5 inhibitors in this pyrrole series.  
 
CHEMISTRY 
Structure-activity relationships (SARs) were developed for the ketone and amide substituents 
of lead compound 5. Regioselective Friedel-Crafts acylation of commercially available methyl 
pyrrole 2-carboxylate (6) using the appropriate acid chloride and aluminium trichloride gave 
methyl esters 7-18 (Scheme 1).  
Hydrolysis of esters 7-18 provided carboxylic acids 19-30, and subsequent amide coupling 
mediated by either CDI or PCl3 furnished inhibitors 31-46. The PCl3-mediated coupling conditions 
proved beneficial with electron-poor amines, where CDI coupling was generally unsuccessful.  
 
Scheme 1. Reagents and conditions; (i) AlCl3, appropriate acid chloride, DCM, 0 °C-RT, 16 h, 
22-82%; (ii) LiOH, THF/H2O, 60 °C, 16 h, 40-99%; (iii) CDI, THF, 70 °C, 3 h; appropriate amine, 
50 °C, 3 h then RT, 16 h, 35-95%, or PCl3, appropriate amine, MeCN, 150 C, MW, 5-30 min, 48-
76%; R groups are defined in Tables 1 and 2. 
 
RESULTS AND DISCUSSION 
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Following successful hit validation [26], attention initially focussed on developing SARs for 
substitution of the aroyl ring of 5 in an attempt to improve potency against ERK5, while retaining 
the most potent 4-picolylamide substituent identified in the initial hit validation campaign [26]. 
Fluoro substitution at the 2-position (32) was beneficial, as was chloro substitution at the 2- or 3-
positions (35, 36). Substitution at the 4-position (34, 37) led to loss of ERK5 inhibition. 2,3- or 
2,6-disubstitution (38, 40) conferred a modest further improvement in potency. 
Due to the similarity between published p38α MAP kinase inhibitors [28] and our hit series, a 
counter-screen against p38α was employed to determine the selectivity of the series. Compounds 
were generally inversely selective for p38α, with the exception of 40 which showed modest 4-fold 
selectivity for ERK5. 
 
Table 1. Biological evaluation of compounds 31-40. 
ID R1 ERK5; IC50 (µM)a p38α; IC50 (µM)b 
31 Ph 40 ± 2.6 - 
32 2-F-phenyl 5.9 ± 5.9 0.36 ± 0.14 
33 3-F-phenyl >120 - 
34 4-F-phenyl >120 - 
35 2-Cl-phenyl 15 ± 2.8 - 
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36 3-Cl-phenyl 6.3 ± 0.1 6.5 ± 1.9 
37 4-Cl-phenyl >120 - 
38 2,3-diF-phenyl 7.0 ± 2.5 2.4 ± 0.75 
39 2,6-diF-phenyl 30 ± 32 0.58 ± 0.27 
40 2,6-diCl-phenyl 4.4 ± 2.1 12.3 ± 4.7 
a ERK5 IC50s determined using an IMAP FP Progressive Binding System kit (Molecular Devices 
#R8127). b p38α IC50s determined against full length p38 protein (Millipore #14-251) in a LANCE 
assay format using a Ulight-MBP peptide substrate. Determinations ± standard deviation (mean of 
n ≥ 4). 
 
Attention turned to the amide substituent. Truncated amide groups, lacking the methylene 
spacer, were synthesised with the aim of improving potency against ERK5 (Table 2). 4-
Pyridylamide (41) was around 30-fold more potent than its methylene spaced analogue (39), 
exhibiting sub-micromolar ERK5 inhibition. Gratifyingly, truncation of the amide substituent led 
to a considerable improvement in selectivity over p38α. The 3-pyridylamine regioisomer (42) 
maintained similar ERK5 potency and selectivity. Replacing one of the fluoro substituents with a 
larger halogen atom, while retaining the second fluoro substituent proved beneficial in terms of 
both potency and selectivity (43-46). Five compounds from this series were tested in a cell-based 
ERK5-dependent MEF2D reporter gene assay. Cellular potency was within 5- to 10-fold of the 
cell-free IC50 values (Table 2), with compounds 43, 45 and 46 having similar profiles. Due to its 
sub-micromolar potency, high selectivity for ERK5 over p38α in cell-free assays, and less than 4-
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fold difference beween isolated enzyme and cell-free assays, compound 46 was selected as a 
representative of the pyrrole carboxmide series for further profiling. Growth inhibition in PC3 cells 
was assessed for compound 46, which exhibited a GI50 of 44 ± 2.8 µM. 
 
Table 2. Biological Evaluation of compounds 41-46. 
ID R1 R2 
ERK5; IC50a 
(µM) 
p38α; IC50b 
(µM) 
ERK5 
MEF2D; IC50c 
(µM)c 
41 2,6-diF 
 
0.90 ± 0.15 100 ± 35 8.0 ± 10 
42 2,6-diF 
 
1.1 ± 0.27 35 ± 0.90 n.d. 
43 2-Cl, 6-F 
 
0.60 ± 0.30 >120 2.3 ± 1.5 
44 2-Cl, 6-F 
 
0.60 ± 0.20 93.2 ± 12.5 4.0 ± 1.4 
45 2-Br, 6-F 
 
0.70 ± 0.20 >120 4.0 ± 2.8 
46 2-Br, 6-F 
 
0.82 ± 0.10 >120 3.0 ± 1.2 
a ERK5 IC50s determined using an IMAP FP Progressive Binding System kit (Molecular Devices 
#R8127). b p38α IC50s determined against full length p38 protein (Millipore #14-251) in a LANCE 
assay format using a Ulight-MBP peptide substrate. Determinations ± standard deviation (mean of 
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n ≥ 4). c Cell-based activity against ERK5 was determined using a transcriptional reporter assay in 
which mutationally activated MEK5 (MEK5D) and ERK5 were co-expressed in HEK293 cells 
and the transactivation domain of the transcription factor MEF2D (an ERK5 substrate) fused to 
the DNA binding domain of the yeast GAL4 protein. ERK5-dependent activity of GAL4-MEF2D 
was assayed using a co-expressed luciferase reporter. Determinations ± standard deviation (mean 
of n = 2). 
 
A crystal structure of the kinase domain of ERK5 in complex with 46 was determined at 2.4 Å 
resolution, revealing the binding mode for the pyrrole series and rationalising the SAR results 
(Figure 2, PDB ID 5O7I). As expected, 46 binds in the ERK5 ATP-binding site. The pyrrole NH 
and amide carbonyl form hydrogen bonds with the backbone carbonyl of Asp138 and amide of 
Met140 from the ERK5 hinge-region, respectively. The 3-pyridinyl substituent lies toward the 
mouth of the ATP-binding pocket, and is twisted 35 out-of-plane with respect to the amide. 
Electron density for the pyridyl ring is less well defined than that for the 4-(2-bromo-6-
fluorobenzoyl)-1H-pyrrole-2-carboxamide moiety, suggesting a degree of rotational freedom 
about the N-C bond. The ketone carbonyl lies in plane with the pyrrole ring, and is oriented toward 
the back of the ATP-binding pocket where it makes a water-mediated hydrogen bond to the 
backbone amide of Phe201. The 2-bromo-6-fluorophenyl moiety lies in an orthogonal plane to the 
pyrrole ring, and occupies a hydrophobic pocket formed by the aliphatic portions of the side-chains 
of Tyr66, Val69, Lys84, Ile115, Leu137, Leu189 and Asp200. This pocket is highly 
complementary in shape to the 2-bromo-6-fluorophenyl moiety, whilst the orthogonal bioactive 
conformation is favoured by ortho-substitution, accounting for the observed SAR around the aroyl 
ring. The side-chain of Tyr66 from the tip of the glycine-rich P-loop that covers the ATP-binding 
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site re-orients to stack edge-to-face against the phenyl ring, explaining the loss of potency for 4-
substituted compounds, 34 and 37. 
 
Figure 2. Compound 46 bound at the ERK5 ATP-binding site (PDB ID 5O7I). (a) Crystal structure 
of the ERK5-46 complex determined at 2.4 Å resolution, shown in coral ribbon with key active-
site residues labelled and shown as sticks, and 46 with carbon atoms in green. The 2Fo-Fc omit 
electron density, contoured at 1.5 σ around 46, is displayed as a blue mesh. (b) As (a) with a 
transparent electrostatic surface drawn over the protein atoms. (c) Top down view of 46 bound 
within the ERK5 ATP-binding site highlighting the potential hydrogen bonding network formed 
with the hinge region (D138-M140), and the potential water mediated hydrogen bond formed with 
D200 of the DFG. 
Compopund 46 progressed into further pharmacokinetic and pharmacological profiling. In both 
human and mouse microsomal stability assays 46 exhibited low intrinsic clearance (HLM Clint <5 
µL/min/mg protein; MLM Clint 26 µL/min/mg protein) and had high flux and a low efflux ratio 
(ER) in a caco-2 cell permeability assay (BA >10 × 10-6 cm/s, ER 0.82). Solubility, as assessed in 
a turbidometric solubility assay (Cyprotex), estimated the precipitation concentration of 46 to be 
>100 µM, (Table 3). 46 had moderate plasma protein binding (Fu 0.06). Compound 46 had an IC50 
of >5 µM against a panel comprising four cytochrome P450 isoforms (2C19, 2C9, 2D6, 3A4). 
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When screened at a concentration of 10 μM against a panel of 456 kinases (DiscoverX), in 
addition to ERK5, 46 inhibited only seven other kinases by ≥ 90% (DCAMKL3, JAK1, SLK, 
MAP3K15, TYK2, JAK2, MST2 and DCAMKL1; full kinome panel inhibition data can be found 
in the supplementary information). Overall, 46 showed good drug-like properties and was 
progressed into in vivo drug metabolism pharmacokinetic (DMPK) studies in mice.   
A 10 mg/kg dose of 46 was administered through both oral and intravenous routes to female 
CD1 mice at 8-10 weeks of age (3 mice per time point). The plasma of these mice was collected 
at eight time points following administration (Table 3). The terminal plasma half-life was 38 min, 
with a plasma clearance of 27 mL/min/kg, and oral bioavailability of 68%. 
Table 3. In vivo pharmacokinetic parameters for 46 dosed in female CD1 mice (Charles River, 
Kent UK) 10 mg/kg either i.v. or p.o. 
Administration PO IV 
Dose (mg/kg) 10 10 
AUC (µg/mL.min) 254 372 
Cmax (µM) 6 25 
Vd (L/kg) - 1.2 
Tmax (min) 15 - 
Clp (mL/min/kg) - 27 
t1/2 (min)  38 
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F (%) 68 - 
 
In vivo efficacy was assessed using a Matrigel plug assay in female CD1 mice (8-10 weeks old) 
and an A2780 human ovarian carcinoma xenograft model in female CD1 nude (nu/nu) mice (8-10 
weeks old). In both studies, the efficacy of 46 was compared to that of the most advanced ERK5 
literature ERK5 inhibitor at the time, XMD8-92 (2). The Matrigel plug assay is a measure of 
angiogenesis and was performed by subcutaneously inoculating mice with 500 µL of Matrigel 
containing basic fibroblast growth factor (bFGF; 500 ng/mL). This induces formation of a Matrigel 
plug, which can be permeated by host cells and leads to formation of new blood vessels. In the 
presence of an anti-angiogenic agent the extent of new blood vessels formed would be reduced. 
Mice were randomised 24 h following Matrigel inoculation, to receive either; vehicle, XMD8-92 
(2) (50 mg/kg, i.p.) or 46 (100 mg/kg, p.o.) twice-daily for 7 days (5 mice per group). On day 7 
the mice were humanely sacrificed and the Matrigel plugs removed and snap frozen in liquid 
nitrogen. The concentration of haemoglobin present could then be determined as a surrogate 
measure for the extent of blood vessel formation. An anti-angiogenic effect was apparent with 
Matrigel plugs from animals treated with both, XMD8-92 (2) (two tailed unpaired t-test, n = 5, p 
= 0.042) and compound 46 (two tailed unpaired t test n = 5 p = 0.0009) having lower concentrations 
of haemoglobin than those from control animals receiving vehicle (Figure 3).  There was no 
significant difference between the two treatments (two tailed unpaired t-test, n = 5, p = 0.367). 
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Figure 3. Haemoglobin levels determined in a bFGF Matrigel plug assay. Female CD1 mice, 5 
per group, were treated with XMD8-92 (2) (50 mg/kg, i.p.) or 46 (100 mg/kg, p.o.) twice-daily for 
7 days and p values determined using an unpaired two-tailed t-test. 
 
In a human tumour xenograft model, mice were inoculated subcutaneously on the right flank 
with 1 × 107 A2780 human ovarian carcinoma cells, and tumours left to grow for 7 days. The mice 
(9 per group) were then randomised to receive either vehicle, XMD8-92 (2) (50 mg/kg, i.p.) or 46 
(100 mg/kg, p.o.) twice-daily for 10 days. Tumour volumes were significantly reduced (as assessed 
by an unpaired two-tailed t-test) in mice treated with either XMD8-92 (2) (62% inhibition; p = 
0.001) or with 46 (57% inhibition; p = 0.002) when compared to the control group (Figure 4a). 
Nadir weight was used as an indicator of drug toxicity. None of the animals lost more than 4% of 
their starting body weight with the nadir body weights being 96% for control, 98% for XMD8-92-
treated and 99% for animals in the 46 treatment group (9 mice per group) (Figure 4b). These initial 
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in vivo studies suggest that an ERK5 inhibitor could have potential as an anti-angiogenic agent and 
thereby constrain solid tumour growth. 
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Figure 4. a). Treatment of female CD1 nude mice bearing A2780 human ovarian carcinoma 
xenografts with vehicle control, XMD8-92 (2) (50 mg/kg, ip) or 46 (100 mg/kg, po) (9 per group). 
Mice were treated twice-daily for 10 days at the end of treatment mean tumour volumes were 
significantly smaller in mice treated with either XMD8-92 (2) (p = 0.001) or with 46 (p = 0.002) 
when compared to the control group (unpaired two-tailed t-test) b). Percent body weight change 
over the course of the study. 
During the course of the study, we became aware of the recently reported activity of the selective 
ERK5 inhibitor XMD8-92 (2) towards BRD4.[24] Thus, the potential of 46 to interact with the 
first bromodomain of BRD4 was assessed using Surface Plasmon Resonance (SPR). In contrast to 
the positive control XMD8-92 (2), no binding was observed from the sensorgram for compound 
46 (Figure 5), confirming that effects seen in the in vivo efficacy models were not due to inhibition 
of BRD4. 
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Figure 5. Characterisation of the binding of 46 and XMD8-92 (2) to BRD4 by SPR. 1:1 steady-
state binding model of 2 and 46 against BRD4, resulting in a Kd of 1.64 µM and no binding, 
respectively. 
 
CONCLUSIONS 
An ERK5 inhibitor with sub-micromolar potency in a cell-free assay has been developed based 
on a pyrrole carboxamide scaffold through structure-based optimisation of the aryl ketone and 
amide substituents. Greater than one-hundred fold selectivity over p38α MAP kinase was attained 
through truncation of the amide substituent. Compound 46 does not interact with the BRD4 
bromodomain. Compound 46 exhibited suitable pharmacokinetics in mouse to permit in vivo 
studies following oral dosing and does not interact with the BRD4 bromodomain. Compound 46 
suppressed both tumour xenograft growth and bFGF-driven Matrigel plug angiogenesis. Further 
development of the pyrrole carboxamide series of ERK5 inhibitors to provide compounds with 
single digit nanomolar ERK5 inhibition in the cell-free ERK5 assay, and sub-micromolar activity 
in cell-based assays will be the subject of a future publication [29]. 
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EXPERIMENTAL METHODS 
Biological Assay Protocols  
ERK5 protein production 
Cloning of ERK5. The cDNA encoding the catalytic domain of human ERK5 (2-409aa) (NCBI 
Accession No. BC009963) was cloned into pFastBac-HTb (Invitrogen), which contains an N-
terminal 6 x His tag and a TEV cleavage site. 
Cloning of ∆N11MEK5DD. Constitutively active mutant form of human MEK5 (NCBI 
Accession No. BC008838) (MEK5DD) was generated by PCR-based site-directed mutagenesis 
(QuikChange  II Site-Directed Mutagenesis kit, Stratagene). The dual phosphorylation sites, 
serine 311 and threonine 315, were replaced with aspartic acid. Truncated MEK5DD lacking the 
N-terminal 11 residues (13-448 aa), termed ∆N11MEK5DD, was cloned into pFastBacGST (a 
modified pFastbac-1 vector that encodes an N-terminal GST tag and a thrombin cleavage site, 
created in-house).  
Baculovirus Production and Protein Expression. Cell Culture: Sf9 suspension cultures grown 
in serum free SF900II medium (Invitrogen) were maintained in shaker flasks at 28 C with 
continuous shaking at 150 rpm.  
GST-∆N11MEK5DD and ERK5 recombinant baculoviruses were generated utilizing the Bac-to-
Bac baculovirus expression system, as suggested by the manufacturer (Invitrogen).  
ERK5 protein was co-expressed with GST-∆N11MEK5DD by co-infecting Sf9 cells, seeded at a 
density of 1x106 cells/mL, with both ERK5 and GST-∆N11MEK5DD viruses at MOIs of 5. 72 h 
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after infection, the cells were harvested by centrifugation at 1500 rpm for 10 min. The cell pellet 
was washed with ice-cold PBS and the cells centrifuged as above. The cell pellet was flash frozen 
in liquid nitrogen and stored at -80 C until processing. 
Protein Purification. 500 mL of harvested SF9 culture lysed by resuspending in 10 mL lysis 
buffer (50 mM HEPES pH 7.87, 150 mM NaCl, 1% Triton X-100, 50 mM imidazole, 1 mini 
EDTA-free complete protease inhibitor tablet (Roche), 1% phosphatase inhibitor cocktail 2 
(Sigma)) and rolling at 4 °C for 45 minutes. Insoluble material removed by centrifugation and 
clarified supernatant applied to a 1 mL HisTrap HP column (GE) pre-equilibrated in Buffer A (50 
mM HEPES pH 7.87, 150 mM NaCl, 50 mM imidazole). Column washed with 10 CV's Buffer A. 
Bound protein eluted with a 20 CV linear gradient from Buffer A to Buffer B (50 mM HEPES pH 
7.87, 150 mM NaCl, 1 M imidazole); all steps run at 0.5 mL/min. 
Fractions containing ERK5/MEK dialysed overnight against Buffer C (50 mM HEPES pH 7.87, 
150 mM NaCl) using slidealyzer dialysis membrane, at 4 °C.  
Dialysed protein loaded onto a 1 mL CaptoQ trap column (GE), washed with 10 CV's of Buffer 
C. Bound protein eluted using an 80 CV linear gradient from Buffer C to Buffer D (50 mM HEPES 
pH 7.87, 1 M NaCl), All steps carried out at 0.5 mL/min flow rates. 
Fractions containing ERK5/MEK pooled and dialysed against Buffer E (50 mM HEPES pH 7.87, 
150 mM NaCl, 25% glycerol, 5 mM DTT), filter sterilised and 250 µL aliquots frozen at -80 °C. 
Batch variable yield from 75 – 240 μg/ml (440 μg – 1069 μg total protein) of ERK5/MEK complex. 
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Biochemical ERK5 activity assay. Compound IC50s were determined against ERK5 using FAM-
EGFR-derived peptide substrate (LVEPLTPSGEAPNQ(K-5FAM)-COOH, Molecular Devices 
#R7129) and an IMAP FP Progressive Binding System kit (Molecular Devices #R8127). 
Compounds were serially diluted 3-fold to generate 10-point curves. Assays were incubated for 2 
h at 37 °C in a 10 µL reaction volume containing ERK5 (5-10 nM depending on batch activity), 
1x IMAP reaction buffer, 1mM DTT, 250 nM peptide substrate, 300 µM ATP and 4% DMSO. 
Detection of phosphorylated product was performed by transferring 1 µL of the enzyme reaction 
above with 9 µL of 1x IMAP reaction buffer and 30 µL of IMAP Binding Solution, prepared as 
per the manufacturer’s instructions, and incubating for 2 h at RT. Fluorescence polarisation was 
measured on a Pherastar (BMG) using an FP 485-520-520 optic module. 
Biochemical p38 activity assay. Compound IC50s were determined against full length p38 protein 
(Millipore #14-251) in a LANCE assay format using a Ulight-MBP peptide substrate (PerkinElmer 
#TRF0109). Compounds were serially diluted as for the ERK5 biochemical assay. Assays were 
incubated for 1 h at 37 °C in a 10 µL reaction volume containing p38 (1-3 nM depending on batch 
activity), 50 mM Tris pH 7.5, 5mM MgCl2, 0.5 mM EGTA, 2 mM DTT, 0.01% Triton X100, 50 
nM peptide substrate, 350 µM ATP and 4% DMSO. Quenching of the reaction and detection of 
phosphorylated product were performed by addition of 10 µL of a mixture of EDTA (5 mM final 
concentration) and LANCE Ultra Europium-anti-phospho-MBP antibody (PerkinElmer 
#TRF0201, 2 nM final concentration), and incubating for 2 h at RT, protected from light. FRET 
was measured on a Pherastar (BMG) using an HTRF 337-665-620 optic module.  
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ERK5-Dependent Dual-Luciferase Reporter Assay. Given the paucity of validated ERK5 
substrates we assessed cell-based activity against ERK5 using a transcriptional reporter assay in 
which mutationally activated MEK5 (MEK5D) was co-expressed in cells together with ERK5 and 
the transactivation domain of the transcription factor MEF2D (an ERK5 substrate) fused to the 
DNA binding domain of the yeast GAL4 protein. ERK5-dependent activity of GAL4-MEF2D was 
assayed using a co-expressed luciferase reporter as previously described [30].  
Plasmids. The HA-ERK5 and EGFP-MEK5D constructs have been described previously[30] and 
were derived from constructs provided by J.D. Lee.  GAL4-MEF2D was a kind gift from J.M. 
McDermott and GAL4 LUC and CMV-Renilla reporters from D. Gillispie, Universidad de La 
Laguna, Spain. 
Cell culture. HEK293 were cultured in DMEM supplemented with 10% FBS at 37 C in an 
atmosphere of 5% CO2 and 95% humidity as described previously [30].  
Luciferase assays. HEK293 were transfected using Lipofectamine 2000 (LifeTechnologies, 
https://www.lifetechnologies.com/uk/en/home/brands/product-
brand/lipofectamine/lipofectamine-2000.html), according to the manufacturer’s instructions.  
ERK5 inhibitors was added to a final concentrations of 30 µM, 10 µM, 3 µM, 1 µM and 0.3 µM 
4 h post transfection. After a further 20 h cells were harvested and processed for firefly and renilla 
luciferase activity using the Dual Luciferase Reporter (Promega, 
http://www.promega.co.uk/products/reporter-assays-and-transfection/reporter-
assays/dual_luciferase-reporter-assay-system/) assay according to the manufacturer’s instructions. 
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Quantification of Cellular Inhibition of ERK5. Raw data was processed using Microsoft Excel and 
GraphPad Prism 6.02, enabling generation of IC50 values. Each data point is the mean of 3 values 
± standard deviation. 
In vivo Experiments 
All in vivo experiments were reviewed and approved by the Newcastle University Animal Welfare 
and ethical review body, and performed according to the Guidelines for the Welfare set out by an 
ad hoc committee of the National Cancer Research Institute (Workman et al, 2010) and national 
law.  
Matrigel Plug Assay Protocol. Matrigel containing basic fibroblast growth factor (bFGF), which 
induces angiogenesis, was injected sub-cutanously into 15 8-10 week old female CD1 mice 
(Charles River, Kent UK). 24 hours post Matrigel inoculation, mice were randomised to receive 
either vehicle, 50 mg/kg XMD8-92 i.p. twice daily for 7 days or 46 p.o. twice daily for 7 days. On 
day 7, mice were killed; Matrigel plugs were removed and snap frozen in liquid nitrogen. 
Haemoglobin was measured using the Drabkin’s method. Drabkin’s reagent (containing sodium 
bicarbonate, potassium ferricyanide and potassium cyanide) allowed quantitative colorimetric 
determination of haemoglobin concentrations in blood. 
Human Tumour Xenograft Model Protocol. Female CD1 nude (nu/nu) mice at 8-10 week old 
(Charles River Kent UK) were inoculated with A2780 cells (human ovarian carcinoma) cells 
subcutaneously on the right flank, and tumour volume was allowed to develop for 7 days to an 
average volume of 72 mm3. Mice were randomized (9 per group) to receive either vehicle, 50 
mg/kg XMD8-92 i.p. or 100 mg/kg 46 p.o. twice daily for 10 days. Tumour volumes were then 
measured using digital calipers three times per week. Statistical analysis of mean tumour volume, 
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at the end of treatment, was performed using an unpaired two tailed t-test. Body weight was 
monitored as an assessment of drug toxicity.  
Pharmacokinetic (PK) Studies. Female CD1 mice 8-10 week old (Charles River, Kent UK) were 
treated with 10 mg/kg of 46 either i.v. or p.o., and were bled by cardiac puncture under terminal 
anaesthesia at selected time points post-treatment (0.083-24 hours, 3 mice/time point). Blood was 
collected into heparinised tubes, and plasma was separated and stored at –20 °C until analysed. 
Drug concentrations were determined by LCMS calibrated with standards prepared in control 
plasma and pharmacokinetic parameters determined using a non-compartmental (trapezoidal) 
method. Terminal half-life was determined using log linear regression of the final six time points 
(r2 > 0.96). 
Crystallographic Protocols. Preparation of ERK5-46 complex crystals. Purified 
unphosphorylated ERK5 kinase domain (residues 46-402) was purchased from Proteros 
Biostructures GmbH and co-crystals with compound were prepared in a similar manner as 
described [31]. ERK5 (46-402) at 11.5 mg mL-1 in storage buffer (50 mM HEPES (pH 6.5), 150 
mM NaCl, 10 % (v/v) glycerol, 2 mM DTT) was mixed with 46 (100 mM in 100 % DMSO) to 
give a final concentration of 1 mM 46 and 1 % (v/v) DMSO.  Complex formation was allowed to 
proceed for two hours on ice.  The sample was then clarified by centrifugation (5 min, 16 000g, 4 
ºC) immediately before use in crystallisation. Crystals were grown by sitting drop vapour diffusion 
at 20 ºC in 96-well MRC plates, by mixing the protein: compound complex with crystallisation 
buffer comprising 5 % (v/v) PEG 6000, 0.1 M MES (pH 6.0), 5 mM DTT in a 1:1 ratio to give a 
0.8 µL drop. Drops were immediately streak seeded with a seed stock prepared from crystals of 
ERK5 with an indazole ERK5 inhibitor (in house series - unpublished structure).  The seed stock 
was prepared by looping two crystals of the ERK5: indazole complex into 2 µL crystallisation 
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buffer (5 % (v/v) PEG 6000, 0.1 M MES (pH 6.0), 5 mM DTT).  The buffer and crystals were 
transferred into a micro-centrifuge tube containing a stabilisation buffer (20 µL 5 % (v/v) PEG 
6000, 0.1 M MES (pH 6.0), 5 mM DTT plus 80 µL 6 % (v/v) PEG 6000, 0.1 M MES (pH 6.25), 
5 mM DTT) and the crystals were crushed by vortexing with a Teflon bead.  The seed stock was 
aliquoted into cryo-tubes, flash frozen in liquid nitrogen, and stored at -80 ºC until use.  
X-ray diffraction data collection, structure solution and refinement for the complex of ERK5 
with 46. Crystals were passed briefly through a cryoprotectant solution comprising 4.9 % (v/v) 
PEG 6000, 70 mM MES (pH 6.0), 3.5 mM DTT, 30 % (v/v) glycerol, 1 % (v/v) DMSO and 10 
mM 46 before flash cooling in liquid nitrogen. Data were collected at 100 K on beamline I04 at 
the DIAMOND Light Source (Oxford, UK).  Data were processed using XDS [32], and programs 
from the CCP4 suite [33] as implemented within autoPROC [34]. The structure was solved by 
molecular replacement using Molrep [35] and a high resolution structure of ERK5 (PDB ID 5BYZ 
[31]) as the search model.  Rounds of manual model completion in Coot [36] were interspersed 
with maximum-likelihood TLS refinement in Buster (v. 2.10.2) [37]. Ligand libraries and 
coordinates were generated from the corresponding SMILES string using grade (v1.2.9, Global 
Phasing Ltd., Cambridge, UK) and cross-validated against the CSD [38] using Mogul [39] after 
fitting the ligand into difference density and reciprocal space refinement. Crystallographic data 
statistics are provided in Table S1. 
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BRD4 Expression, Purification and Surface Plasmon Resonance Protocols 
Expression and purification of recombinant BRD4 bromodomain 1. Harvested bacterial cells 
were resuspended in lysis buffer comprising 50 mM HEPES (pH 7.4), 200 mM NaCl, 10 mM 
imidazole, 0.5 mg mL-1  lysosyme, and 0.2 mg mL-1  DNAse at 4 ºC for 1 h. After sonication and 
centrifugation (1 h at 35,000 x g), the supernatant was purified by immobilized Ni2+ ion affinity 
chromatography. The peak fractions were pooled and incubated with GST tagged HRV 3C 
protease (50:1) at 4 ºC overnight. The cleaved His-tag was separated from BRD4 by size exclusion 
chromatography using a Superdex 75 (26/60) column (GE Healthcare), equilibrated and run in 50 
mM HEPES (pH 7.4), 200 mM NaCl and 1 mM DTT. All purification steps were performed using 
an ÄKTA Pure (GE Healthcare) at 4 ºC. 
Surface Plasmon Resonance. SPR-based ligand binding assays were performed using a BIAcore 
S200 (GE Healthcare) at 25 ºC using single cycle affinity. Immobilisation of BRD4 was achieved 
using standard amine coupling on a CM5 chip surface. The surface was prepared through 
activation with EDC/NHS, followed by injection of 10 µg mL-1 BRD4 until a target level of 8000 
RU was reached. The surface was then quenched using 1 M ethanolamine and washed with running 
buffer (10 mM HEPES, 150 mM NaCl, 0.01 % (v/v) TWEEN20, 0.5 mM TCEP and 1 % (v/v) 
DMSO) at a flow rate of 30 µL min-1. XMD8-92 and 46 were injected in a dose-response manner 
(nine points ranging from 0-20 µM) with contact time 30sec and dissociation time 160sec in series 
across the reference and BRD4-immobilised flow cells using solvent correction to account for bulk 
refractive index changes. The reference channel response was subtracted from the BRD4-
immobilised channel response and dose-response data were fitted using an affinity steady-state 1:1 
binding model to determine the Kd. 
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Accession codes 
The coordinates for the ERK5-46 complex has been deposited in the wwPDB under accession 
number 5O7I.  
 
Summary of Generic Analytical and Chromatographic Conditions. All commercial reagents 
were purchased from Sigma-Aldrich Chemical Company, Alfa Aesar, Apollo Scientific or Tokyo 
Chemical Industry UK Ltd. The chemicals were of the highest available purity. Unless otherwise 
stated, chemicals were used as supplied without further purification. Anhydrous solvents were 
obtained from AcroSealTM or Aldrich SureSeal™ bottles and were stored under nitrogen. Petrol 
refers to the fraction with a boiling point between 40 and 60 °C. Thin layer chromatography utilised 
to monitor reaction progress was conducted on plates pre-coated with silica gel Merck 60F254 or 
Merck NH2F254S. The eluent was as stated (where this consisted of more than one solvent, the 
ratio is stated as volume:volume) and visualisation was either by short wave (254 nm) ultraviolet 
light, or by treatment with the visualisation reagent stated followed by heating. ‘Flash’ medium 
pressure liquid chromatography (MPLC) was carried out either on a Biotage SP4 automated 
purification system or a Varian 971-FP automated purification system, using pre-packed Varian 
or Grace silica or amino-bonded silica cartridges. All reactions carried out in a microwave were 
performed in a Biotage Initiator with Sixty robot. Melting points were determined using a VWR 
Stuart SMP40 apparatus and are uncorrected. 1H, 13C and 19F nuclear magnetic resonance (NMR) 
spectra were obtained as either CDCl3, MeOD or DMSO-d6 solutions and recorded at 500 MHz, 
126 MHz and 471 MHz, respectively, on a Bruker Avance III 500 spectrometer. Where 13C NMR 
data are not quoted, insufficient material was available or problems obtaining high resolution 
spectra were encountered. Chemical shifts are quoted in parts per million (δ) referenced to the 
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appropriate deuterated solvent employed. Multiplicities are indicated by s (singlet), d (doublet), t 
(triplet), q (quartet), quin (quintet), m (multiplet), br (broad) or combinations thereof. Coupling 
constant values are given in Hz. Homonuclear and heteronuclear two dimensional NMR 
experiments were used where appropriate to facilitate assignment of chemical shifts. LC-MS was 
carried out on a Waters Acquity UPLC system with PDA and ELSD employing positive or 
negative electrospray modes as appropriate to the individual compound. High resolution mass 
spectrometry (HRMS) was performed by the EPSRC UK National Mass Spectrometry Facility, 
Swansea University, Singleton Park, Swansea, SA2 8PP. FTIR spectra were recorded on either a 
Bio-Rad FTS 3000MX diamond ATR or an Agilent Cary 630 FTIR as a neat sample. UV spectra 
were obtained using a U-2001 Hitachi Spectrophotometer with the sample dissolved in ethanol. 
The purity of compounds was assessed by high performance liquid chromatography (HPLC). All 
tested compounds were ≥95% purity. The HPLC instrument was an Agilent 1200 equipped with a 
photodiode array detector (190-400 nm). Sample temperature, ambient; injection volume, 5 L; 
flow rate, 1mL/min. 5% to 100% MeCN gradient over 9 min and an isocratic hold at 100% MeCN 
for 2.5 min, before returning to initial conditions. Mobile phase A = 0.1% ammonia in water or 
0.1% formic acid in water, mobile phase B = MeCN. Column: Waters XSELECT CSH C18, 5 μm, 
4.6 mm × 150 mm. Column maintained at ambient temperature. 
General Synthetic Procedures 
General procedure A: To a suspension of AlCl3 (2.5 eq.) in DCM (1 mL/mmol AlCl3) at 0 C 
was added the relevant acid chloride (2 eq.) followed by methyl 1H-pyrrole-2-carboxylate (1 eq.). 
The resulting mixture was allowed to reach RT and stirred for 16 h. The reaction was quenched at 
0 C with a 1 M aqueous solution of HCl (20 mL). The product was extracted with DCM (3 × 100 
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mL), washed with an aqueous saturated solution of NaHCO3 (2 × 100 mL) and brine (100 mL). 
Combined organic layers were dried over Na2SO4 and concentrated in vacuo.  
General procedure B: To a solution of pyrrole ester (1.0 eq.) in THF (8 mL/mmol) was added 
LiOH (20 eq.) in water (13 mL/mmol). The resulting mixture was heated at 60 °C for 18 h, cooled 
to RT and acidified to pH 4-5 with aq. HCl (1.0 M). The product was extracted into EtOAc (100 
mL/mmol), washed with water (100 mL/mmol), brine (100 mL/mmol) and dried over Na2SO4. 
The solvent was removed under vacuum to obtain the product. 
General procedure C: A solution of carbonyldiimidazole (2.0 eq.) and the required carboxylic 
acid (1.0 eq.) in THF (5 mL/mmol) was heated to 70 ºC for 3 h. The appropriate amine (2.5 eq.) 
was added and the mixture heated at 50 °C for 3 h then at RT for 16 h. The product was extracted 
into EtOAc (50 mL/mmol), washed with water (50 mL/mmol), brine (50 mL/mmol) and dried over 
Na2SO4. The solvent was removed under vacuum to give the crude product. 
General procedure D: The appropriate carboxylic acid (1.0 equiv.) was dissolved in MeCN (5 
mL/mmol pyrrole) before the relevant amine (2.5 equiv.) was added followed by phosphorus 
trichloride (1.0 equiv.). The mixture was heated using microwave irradiation at 150 C for 5 min. 
The reaction was quenched with a few drops of H2O and the solvent removed in vacuo. The residue 
was re-dissolved in EtOAc (50 mL/mmol pyrrole) and washed with a saturated aqueous solution 
of NaHCO3 (50 mL/mmol pyrrole) before being extracted with EtOAc (3 × 30 mL/mmol pyrrole). 
The combined organic extracts were dried over Na2SO4, and the filtrate concentrated in vacuo to 
afford the crude product. 
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Compound Syntheses 
Methyl-4-benzoyl-1H-pyrrole-2-carboxylate (7) Prepared according to general procedure A 
using methyl-2-pyrrole carboxylate (112 mg, 0.90 mmol), benzoyl chloride (205 µL, 1.79 mmol) 
and aluminium chloride (298 mg, 2.23 mmol) in DCM (2.2 mL). Purification via MPLC (silica; 
0-40% EtOAc in petroleum ether) gave 7 as a yellow solid (199 mg, 96%); Rf 0.40 (50% EtOAc 
in petroleum ether); mp 148-149 °C; λmax (EtOH)/nm 285, 238; IR υmax/cm-1 3293, 1715, 1620, 
1596, 1555; 1H NMR (300 MHz, DMSO-d6)  3.81 (3H, s, OCH3), 7.15 (1H, s, H-pyrrole), 7.48-
7.67 (4H, m, 3 × H-Ar and H-pyrrole), 7.73-7.83 (2H, m, 2 x H-Ar), 12.76 (1H, s, NH); 13C NMR 
(75 MHz, DMSO-d6)  30.1 (OCH3), 115.5 (CH-pyrrole), 123.2 (C), 124.2 (C), 128.0 (4 x C-Ar), 
128.7 (CH-pyrrole), 131.3 (C-Ar), 138.6 (C-Ar), 160.1 (COOMe), 188.6 (CO); HRMS (ES+) calcd 
for C13H12O3N [M+H]
+ 230.0812, found 230.0811; Anal. calcd for C13H11NO3: C, 68.11%, H, 
4.84%, N, 6.11%, found: C, 68.33%, H, 4.78%, N, 6.21%. 
Methyl 4-(2-fluorobenzoyl)-1H-pyrrole-2-carboxylate (8) Prepared according to general 
procedure A using methyl-2-pyrrole carboxylate (3.0 g, 24.0 mmol), 2-fluorobenzoyl chloride (5.7 
mL, 48.0 mmol) and aluminium chloride (5.52 g, 60.0 mmol) in DCM (60 mL). Purification via 
precipitation (EtOAc in petroleum ether) gave 8 as a yellow solid (4.16 g, 70%); mp 129-130 °C; 
λmax (EtOH)/nm 284, 234; IR υmax/cm-1 3291, 1722, 1632, 1553; 1H NMR (300 MHz, DMSO-d6) 
 3.79 (3H, s, OCH3), 7.06 (1H, s, H-pyrrole), 7.27-7.37 (2H, m, H-pyrrole and H-Ar), 7.40-7.66 
(3H, m, 3 x H-Ar), 12.79 (1H, s, NH); 13C NMR (75 MHz, DMSO-d6)  51.1 (OCH3), 114.8 (CH-
pyrrole), 115.8 (d, JC-F = 21.5 Hz, C-Ar), 123.6 (C), 124.1 (d, JC-F = 3.3 Hz, C-Ar), 125.2 (C), 
127.7 (d, JC-F = 15.3 Hz, C), 129.1 (CH-pyrrole), 129.2 (d, JC-F = 3.1 Hz, C-Ar), 132.2 (d, JC-F = 8 
Hz, ArH), 158.5 (d, JC-F = 247.3 Hz, C-F), 160.0 (COOMe), 185.6 (CO); HRMS (ES
+) calcd for 
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C13H10FNO3 [M+H]
+ 248.0717, found 248.0717; Anal. calcd for C13H10FNO3: C, 63.16%, H, 
4.08%, N, 5.67%, found: C, 63.31%, H, 3.92%, N, 5.51%. 
Methyl 4-(3-fluorobenzoyl)-1H-pyrrole-2-carboxylate (9) Prepared according to general 
procedure A using methyl-2-pyrrole carboxylate (400 mg, 3.20 mmol), 3-fluorobenzoyl chloride 
(0.76 mL, 6.40 mmol) and aluminium chloride (766 mg, 7.99 mmol) in DCM (8 mL). Purification 
via MPLC (silica; 0-10% EtOAc in petroleum ether) gave 9 as a pale yellow solid (585 mg, 74%); 
Rf 0.16 (20% EtOAc in petroleum ether); mp 128-130 ºC; λmax (EtOH)/nm 286, 238; IR υmax/cm-1 
3302, 1716, 1624; 1H NMR (300 MHz, DMSO-d6) δ 3.82 (3H, s, CH3), 7.17 (1H, s, H-pyrrole), 
7.46-7.50 (1H, m, H-Ar), 7.53-7.56 (1H, m, H-Ar), 7.58-7.65 (2H, m, 2 × H-Ar), 7.63 (1H, s, H-
pyrrole), 12.79 (1H, s br, NH); 13C NMR (75 MHz, DMSO-d6) δ 51.8, 115.1, 115.4, 116.2, 118.8, 
119.1, 124.2, 124.6, 124.9, 129.8, 131.0, 131.1, 141.5, 160.8, 162.5, 187.9; 19F NMR (470 MHz, 
DMSO-d6) δ -112.3; MS (ES+) m/z 248.8 [M+H]+. 
Methyl 4-(4-fluorobenzoyl)-1H-pyrrole-2-carboxylate (10) Prepared according to general 
procedure A using methyl-2-pyrrole carboxylate (400 mg, 3.20 mmol), 4-fluorobenzoyl chloride 
(0.76 mL, 6.4 mmol) and aluminium chloride (766 mg, 7.99 mmol) in DCM (8 mL). Purification 
via MPLC (silica; 0-10% EtOAc in petroleum ether) gave 10 as a yellow solid (595 mg, 75%); Rf 
0.12 (20% EtOAc in petroleum ether); mp 154-156 ºC; λmax (EtOH)/nm 285, 237; IR υmax/cm-1 
1724, 1627; 1H NMR (300 MHz, DMSO-d6) δ 3.82 (3H, s, CH3), 7.16 (1H, s, H-pyrrole), 7.35-
7.38 (2H, m, 2 × H-Ar), 7.60 (1H, s, H-pyrrole), 7.87-7.90 (2H, m, 2 × H-Ar), 12.76 (1H, s br, 
NH); 13C NMR (75 MHz, DMSO-d6) δ 51.5, 115.5, 115.9, 123.6, 124.2, 129.4, 131.4, 135.3, 160.5, 
164.2, 187.5; 19F NMR (470 MHz, DMSO-d6) δ -107.9; MS (ES+) m/z 248.9 [M+H]+.  
Methyl 4-(2-chlorobenzoyl)-1H-pyrrole-2-carboxylate (11) Prepared according to general 
procedure A using methyl-2-pyrrole carboxylate (400 mg, 3.20 mmol), 2-chlorobenzoyl chloride 
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(0.81 mL, 6.40 mmol) and aluminium chloride (766 mg, 7.99 mmol) in DCM (8 mL). Purification 
via MPLC (silica; 0-10% EtOAc in petroleum ether) gave 11 as a beige solid (630 mg, 74%); Rf 
0.12 (20% EtOAc in petroleum ether); mp 137-139 ºC; λmax (EtOH)/nm 346, 283, 232; IR υmax/cm-
1 3192, 1710, 1619; 1H NMR (300 MHz, DMSO-d6) δ 3.79 (3H, s, CH3), 6.98 (1H, dd, J = 1.8 and 
2.5 Hz, H-pyrrole), 7.40 (1H, dd, J = 1.8 and 3.3 Hz, H-pyrrole), 7.44-4.49 (2H, m, 2 × H-Ar), 
7.52-7.55 (1H, m, H-Ar), 7.56-7.58 (1H, m, H-Ar), 12.80 (1H, s br, NH); 13C NMR (125 MHz, 
DMSO-d6) δ 51.6, 115.2, 124.1, 125.2, 127.1, 128.5, 129.4, 129.9, 130.0, 131.2, 139.2, 160.4, 
188.1; MS (ES+) m/z 264.3 [M+H]+. 
Methyl 4-(3-chlorobenzoyl)-1H-pyrrole-2-carboxylate (12) Prepared according to general 
procedure A using methyl-2-pyrrole carboxylate (400 mg, 3.20 mmol), 3-chlorobenzoyl chloride 
(0.82 mL, 6.4 mmol) and aluminium chloride (766 mg, 7.99 mmol) in DCM (8 mL). Purification 
via MPLC (silica; 0-10% EtOAc in petroleum ether) gave 12 as an off-white solid (490 mg, 60%); 
Rf 0.45 (50% EtOAc in petroleum ether); mp 126-128 ºC; λmax (EtOH)/nm 288, 237; IR υmax/cm-1 
1724, 1624; 1H NMR (500 MHz, DMSO-d6) δ 3.82 (3H, s, OCH3), 7.16 (1H, s, H-pyrrole), 7.58 
(1H, dd, J = 7.9 and 8.0 Hz, H-Ar), 7.63 (1H, s, H-pyrrole), 7.70-7.71 (1H, m, H-Ar), 7.74-7.76 
(2H, m, 2 × H-Ar), 12.81 (1H, s br, NH); 13C NMR (125 MHz, DMSO-d6) δ 51.6, 115.8, 123.8, 
124.9, 127.2, 128.0, 129.8, 130.6, 131.7, 133.4, 140.7, 160.5, 187.6; MS (ES+) m/z 262.0 [M+H]+. 
Methyl 4-(4-chlorobenzoyl)-1H-pyrrole-2-carboxylate (13) Prepared according to general 
procedure A using methyl-2-pyrrole carboxylate (400 mg, 3.20 mmol), 4-chlorobenzoyl chloride 
(0.82 mL, 6.40 mmol) and aluminium chloride (766 mg, 7.99 mmol) in DCM (8 mL). Purification 
via MPLC (silica; 0-10% EtOAc in petroleum ether) gave 13 as a beige solid (690 mg, 82%); Rf 
0.12 (20% EtOAc in petroleum ether); mp 176-178 ºC; λmax (EtOH)/nm 244; IR υmax/cm-1 3169, 
1716, 1620; 1H NMR (300 MHz, DMSO-d6) δ 3.81 (3H, s, CH3), 7.16 (1H, s, H-pyrrole), 7.60 
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(2H, d, J = 8.4 Hz, 2 × H-Ar), 7.61 (1H, s, H-pyrrole), 7.81 (2H, d, J = 8.4 Hz, 2 × H-Ar), 12.78 
(1H, s br, NH); 13C NMR (75 MHz, DMSO-d6) δ 51.8, 116.2, 124.1, 124.6, 129.0, 129.7, 130.7, 
137.1, 137.9, 160.8, 188.1; MS (ES+) m/z 264.4 [M+H]+.  
Methyl 4-(2,3-difluorobenzoyl)-1H-pyrrole-2-carboxylate (14) Prepared according to general 
procedure A using methyl-2-pyrrole carboxylate (400 mg, 3.20 mmol), 2,3-difluorobenzoyl 
chloride (1.13 g, 0.80 mL, 6.4 mmol) and aluminium chloride (766 mg, 7.99 mmol) in DCM (8 
mL). Purification via MPLC (silica; 0-10% EtOAc in petroleum ether) gave 14 as a yellow solid 
(250 mg, 30%); Rf 0.13 (20% EtOAc in petroleum ether); mp 159-160 ºC; λmax (EtOH)/nm 379, 
286, 234; IR υmax/cm-1 3323, 1720, 1631; 1H NMR (300 MHz, DMSO-d6) δ 3.87 (3H, s, CH3), 
7.11 (1H, s, H-pyrrole), 7.33-7.38 (2H, m, 2 × H-Ar), 7.60 (1H, s, H-pyrrole), 7.61-7.68 (1H, m, 
H-Ar), 12.85 (1H, s br, NH); 13C NMR (75 MHz, DMSO-d6) δ 51.6, 115.5, 119.6, 124.1, 124.8, 
125.1, 125.2, 129.8, 130.4, 146.8, 149.7, 160.4, 184.7; 19F NMR (470 MHz, DMSO-d6) δ -137.7, 
-141.3; MS (ES+) m/z 264.0 [M-H]-. 
Methyl 4-(2,6-difluorobenzoyl)-1H-pyrrole-2-carboxylate (15) Prepared according to general 
procedure A using methyl-2-pyrrole carboxylate (400 mg, 3.20 mmol), 2,6-difluorobenzoyl 
chloride (1.13 g, 0.80 mL, 6.4 mmol) and aluminium chloride (766 mg, 7.99 mmol) in DCM (8 
mL). Purification via MPLC (silica; 0-10% EtOAc in petroleum ether) gave 15 as an orange solid 
(180 mg, 22%); Rf 0.17 (20% EtOAc in petroleum ether); mp 132-124 ºC; λmax (EtOH)/nm 279, 
264; IR υmax/cm-1 1732, 1624; 1H NMR (500 MHz, DMSO-d6) δ 3.57 (3H, s, CH3), 7.04 (1H, s, 
H-pyrrole), 7.23-7.28 (2H, m, 2 × H-Ar), 7.58 (1H, s, H-pyrrole), 7.59-7.67 (1H, m, H-Ar), 12.79 
(1H, s br, NH); 13C NMR (125 MHz, DMSO-d6) δ 51.6, 112.2, 114.6, 117.5, 124.5, 125.9, 130.14, 
132.3, 158.7, 160.3, 181.6; 19F  NMR (470 MHz, DMSO-d6) δ -114.1; MS (ES+) m/z 266.5 
[M+H]+ .  
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Methyl 4-(2,6-dichlorobenzoyl)-1H-pyrrole-2-carboxylate (16) Prepared according to general 
procedure A using methyl-2-pyrrole carboxylate (400 mg, 3.20 mmol), 2,6-dichlorobenzoyl 
chloride (0.92 mL, 6.40 mmol) and aluminium chloride (766 mg, 7.99 mmol) in DCM (8 mL). 
Purification via MPLC (silica; 0-10% EtOAc in petroleum ether) gave 16 as a white solid (700 
mg, 73%); Rf 0.19 (20% EtOAc in petroleum ether); mp 184-186 ºC; λmax (EtOH)/nm 282, 226; 
IR υmax/cm-1 3219, 1726, 1641; 1H NMR (300 MHz, DMSO-d6) δ 3.79 (3H, s, CH3), 6.96 (1H, d, 
J = 1.6 Hz, H-pyrrole), 7.49 (1H, d, J = 1.6 Hz, H-pyrrole), 7.52-7.55 (1H, m, H-Ar), 7.58-7.60 
(2H, m, 2 ×H-Ar), 12.87 (1H, s br, NH); 13C NMR (125 MHz, DMSO-d6) δ 51.6, 114.6, 124.5, 
124.6, 128.5, 129.9, 130.4, 131.5, 138.0, 160.2, 185.6; MS (ES+) m/z 298.1 [M+H]+.  
Methyl 4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylate (17) Prepared according to 
general procedure A using methyl-2-pyrrole carboxylate (3.00 g, 23.80 mmol), 2-chloro-6-
fluorobenzoyl chloride (6.40 mL, 47.60 mmol) and aluminium trichloride (7.93 g, 59.50 mmol) in 
DCM (40 mL). Purification via MPLC (silica; 0-80% EtOAc in petroleum ether) gave 17 as a 
white solid (4.20 g, 63%); Rf 0.48 (50% EtOAc in petroleum ether); mp 183-184 °C; λmax 
(EtOH)/nm 282, 232; IR υmax/cm-1 3224, 1732, 1639, 1563; 1H NMR (500 MHz, DMSO-d6) δ 7.00 
(1H, s, H-3), 7.37-7.40 (1H, m, H-5’), 7.46 (1H, d, J = 8.3 Hz, H-3’), 7.54 (1H, dd, J = 1.5 and 3.3 
Hz, H-5), 7.58 (1H, ddd, J = 6.3, 8.3 and 8.3 Hz, H-4’); 13C NMR (125 MHz, DMSO-d6) δ 51.7, 
114.6, 115.0, 124.5, 125.3, 125.8, 127.8, 130.1, 130.3, 131.9, 158.6, 160.2, 183.7; 19F NMR (470 
MHz, DMSO-d6) δ -114.0; HRMS m/z calcd for C13H1035ClFNO3 [M+H]+ 282.0328, found 
282.0331. 
Methyl 4-(2-bromo-6-fluorobenzoyl)-1H-pyrrole-2-carboxylate (18) Prepared according to 
general procedure A using methyl-2-pyrrole carboxylate (429 mg, 3.43 mmol), 2-bromo-6-
fluorobenzoylchloride (1.62 g, 6.85 mmol), aluminium trichloride (1.15 g, 8.56 mmol) in DCM 
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(10 mL). Purification via MPLC (silica; 0-50% EtOAc in petroleum ether) gave 18 as a white solid 
(760 mg, 68%); Rf 0.51 (50% EtOAc in petroleum ether); mp 185-186 °C; λmax (EtOH)/nm 280; 
IR υmax/cm-1 3229, 1731, 1638, 1563; 1H NMR (500 MHz, DMSO-d6) δ 3.80 (3H, s, CH3), 7.00 
(1H, s, H-3), 7.39-7.43 (1H, m, H-5’), 7.50 (1H, ddd, J = 6.3, 8.3 and 8.3 Hz, H-4’), 7.52 (1H, s, 
H-5), 7.59 (1H, d, J = 8.3 Hz, H-3’), 12.90 (1H, br s, NH); 13C NMR (125 MHz, DMSO-d6) δ  
51.6,  114.7, 115.4, 118.9, 124.5, 125.0, 128.8, 130.4, 132.2, 158.4, 160.3, 184.6; 19F NMR (470 
MHz, DMSO-d6) δ -113.6; HRMS m/z calcd for C13H1079BrFNO3 [M+H]+ 325.9823, found 
325.9830. 
4-Benzoyl-1H-pyrrole-2-carboxylic acid (19) Prepared according to general procedure B using 
methyl 4-benzoyl-1H-pyrrole-2-carboxylate 7 (184 mg, 0.80 mmol), LiOH (676 mg, 16.1 mmol) 
in THF/H2O (5.0 mL/4.0 mL) to give 19 as a pale pink solid (161 mg, 94%); Rf 0.67 (10% MeOH 
and 10% AcOH in DCM); mp 225-226 °C; λmax (EtOH)/nm 285, 237; IR υmax/cm-1 3333, 1667, 
1624, 1549; 1H NMR (300 MHz, DMSO-d6) δ 7.11 (1H, s, H-pyrrole), 7.44-7.67 (4H, m, 3 × H-
Ar and H-pyrrole), 7.72-7.84 (2H, m, 2 × H-Ar), 12.55 (1H, s, NH); 13C NMR (75 MHz, DMSO-
d6) δ 115.1 (CH-pyrrole), 124.1 (C), 124.6 (C), 128.1 (4 x C-Ar), 128.4 (CH-pyrrole), 131.4 (C-
Ar), 138.8 (C-Ar), 161.1 (COOMe), 188.8 (CO); HRMS (ES+) calcd for C12H9NO3 [M+H]
+ 
216.0655, found 216.0655; Anal. calcd for C12H9NO3: C, 66.97%, H, 4.22%, N, 6.51%, found: C, 
66.81%, H, 4.17%, N, 6.33%. 
4-(2-Fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (20) Prepared according to general 
procedure B using methyl 4-(2-fluorobenzoyl)-1H-pyrrole-2-carboxylate 8 (2.0 g, 8.1 mmol), 
LiOH (3.9 g, 162 mmol) in THF/H2O (30 mL/50 mL) to give 20 as a pale pink solid (1.28 g, 68%); 
mp 181-182 °C, λmax (EtOH)/nm 284, 234. IR υmax/cm-1 3339, 3301, 1688, 1630, 1561, 1483; 1H 
NMR (300 MHz, DMSO-d6) δ 7.01 (1H, s, H-pyrrole), 7.25-7.39 (2H, m, 2 x H-Ar), 7.43 (1H, s, 
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H-pyrrole), 7.49-7.66 (2H, m, 2 x H-Ar), 12.61 (1H, s, NH), 12.87 (1H, s, OH); 13C NMR (75 
MHz, DMSO-d6) δ 114.5 (CH-pyrrole), 115.8 (d, JC-F = 21.5 Hz, C-Ar), 124.2 (d, JC-F = 3.2 Hz, 
C-Ar), 124.9 (C), 125.2 (C), 127.8 (d, JC-F = 15.8 Hz, C), 128.8 (CH-pyrrole), 129.3 (d, JC-F = 3.0 
Hz, C-Ar), 132.2 (d, JC-F = 8.3 Hz, ArH), 158.5 (d, JC-F = 247.0 Hz, C-F), 161.0 (COOH), 185.7 
(CO); HRMS (ES+) calcd for C12H8NO3F [M+H]
+ 234.0561, found 234.0561. 
4-(3-Fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (21) Prepared according to general 
procedure B using: methyl 4-(3-fluorobenzoyl)-1H-pyrrole-2-carboxylate 9 (200 mg, 0.81 mmol), 
LiOH (1.55 g, 16.2 mmol) in THF/H2O (5.5 mL/8.2 mL) to give 21 as an orange solid (185 mg, 
98%); Rf 0.06 (10% MeOH in EtOAc); mp 218-219 ºC; λmax (EtOH)/nm 289, 237; IR υmax/cm-1 
3238, 1692, 1613; 1H NMR (300 MHz, DMSO-d6) δ 7.11 (1H, m, H-pyrrole), 7.45-7.50 (1H, m, 
H-Ar), 7.52-7.55 (1H, m, H-Ar), 7.56 (1H, dd, J = 1.5 and 3.1 Hz, H-pyrrole), 7.57-7.64 (2H, m, 
2 × H-Ar), 12.60 (1H, s br, NH), 12.85 (1H, s, COOH); 13C NMR (75 MHz, DMSO-d6) δ 115.1, 
115.4, 115.7, 118.7, 119.0, 124.4, 124.9, 125.5, 129.4, 130.9, 131.1, 141.6, 141.7, 161.7, 162.3, 
185.1; 19F NMR (470 MHz, DMSO-d6) δ -112.3; MS (ES+) m/z 235.2 [M+H]+.   
4-(4-Fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (22) Prepared according to general 
procedure B using methyl 4-(4-fluorobenzoyl)-1H-pyrrole-2-carboxylate 10 (300 mg, 1.2 mmol), 
LiOH (2.33 g, 24.3  mmol) in THF/H2O (7.0 mL/10.5 mL) to give 22 as an off-white solid (110 
mg, 40%); Rf 0.07 (EtOAc); mp: 224-225 ºC; λmax (EtOH)/nm 253, 236; IR υmax/cm-1 3372, 1667, 
1622; 1H NMR (300 MHz, DMSO-d6) δ 7.06 (1H, s, H-pyrrole), 7.32-7.38 (2H, m, 2 × H-Ar), 7.49 
(1H, s, H-pyrrole), 7.85-7.89 (2H, m, 2 × H-Ar), 12.49 (1H, s br, NH), 13.00 (1H, s br, COOH); 
13C NMR (75 MHz, DMSO-d6) δ 114.8, 115.5, 124.0, 128.5, 131.3, 135.5, 161.7, 164.1, 187.7; 
19F NMR (470 MHz, DMSO-d6) δ -108.2; MS (ES-) m/z 232.1 [M-H]-.  
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4-(2-Chlorobenzoyl)-1H-pyrrole-2-carboxylic acid (23) Prepared according to general 
procedure B using methyl 4-(2-chlorobenzoyl)-1H-pyrrole-2-carboxylate 11 (230 mg, 0.76 mmol), 
LiOH (1.45 g, 15.2 mmol) in THF/H2O (5.5 mL/8.2 mL) to give 23 as an off-white solid (155 mg, 
82%); Rf 0.32 (10% MeOH in EtOAc); mp 219-220 ºC; λmax (EtOH)/nm 283, 232, 211; IR υmax/cm-
1 3294, 1668, 1636; 1H NMR (500 MHz, DMSO-d6) δ 6.94 (1H, d, J = 1.6 and 2.2 Hz, H-pyrrole), 
7.31 (1H, d, J = 1.6 and 3.3 Hz, H-pyrrole), 7.44-7.49 (2H, m, 2 × H-Ar), 7.52-7.55 (1H, m, H-
Ar), 7.57-7.58 (1H, m, H-Ar), 12.61 (1H, s br, NH), 12.88 (1H, s, COOH); 13C NMR (125 MHz, 
DMSO-d6) δ 114.7, 125.1, 125.4, 127.1, 128.5, 129.4, 129.5, 129.8, 131.1, 139.3, 161.4, 188.2; 
MS (ES+) m/z 250.3 [M+H]+. 
4-(3-Chlorobenzoyl)-1H-pyrrole-2-carboxylic acid (24) Prepared according to general 
procedure B using methyl 4-(3-chlorobenzoyl)-1H-pyrrole-2-carboxylate 12 (300 mg, 1.14 mmol), 
LiOH (2.2 g, 23 mmol) in THF/H2O (8.3 mL/12.4 mL) to give 24 as an off-white solid (130 mg, 
47%); Rf 0.09 (10% MeOH in EtOAc); mp 282-284 ºC; λmax (EtOH)/nm 288, 236; IR υmax/cm-1 
3335, 1628, 1562; 1H NMR (500 MHz, DMSO-d6) δ 6.96 (1H, d, J = 1.9 Hz, H-pyrrole), 7.42 (1H, 
d, J = 1.9 Hz, H-pyrrole), 7.55-7.58 (1H, m, H-Ar), 7.67-7.69 (1H, m, H-Ar), 7.72-7.74 (2H, m, 2 
× H-Ar); 13C NMR (125 MHz, DMSO-d6) δ 113.2, 123.4, 127.1, 127.8, 127.9, 130.4, 131.3, 133.2, 
141.2, 162.4, 187.8; MS (ES-) m/z 247.9 [M-H]-. 
4-(4-Chlorobenzoyl)-1H-pyrrole-2-carboxylic acid (25) Prepared according to general 
procedure B using methyl 4-(4-chlorobenzoyl)-1H-pyrrole-2-carboxylate 13 (240 mg, 0.76 mmol), 
LiOH (1.45 g, 15.2 mmol) in THF/H2O (5.5 mL/8.2 mL) to give 25 as an off-white solid (140 mg, 
74%); Rf 0.24 (10% MeOH in EtOAc); mp 245-246 ºC; λmax (EtOH)/nm 242; IR υmax/cm-1 3207, 
1672, 1626; 1H NMR (300 MHz, DMSO-d6) δ 7.10 (1H, s, H-pyrrole), 7.54 (1H, s, H-pyrrole), 
7.60 (2H, d, J = 8.4 Hz, 2 × H-Ar), 7.81 (2H, d, J = 8.4 Hz, 2 × H-Ar), 12.59 (1H, s br, NH), 12.86 
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(1H, s br, COOH); 13C NMR (125 MHz, DMSO-d6) δ 115.4, 124.0, 125.0, 128.6, 129.1 (CH-
pyrrole), 130.4 (CH-Ar), 136.6, 137.5, 161.5 (C=O), 187.8 (C=O); MS (ES+) m/z 250.2 [M+H]+.  
4-(2,3-Difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (26) Prepared according to general 
procedure B using methyl 4-(2,3-difluorobenzoyl)-1H-pyrrole-2-carboxylate 14 (250 mg, 0.9 
mmol), LiOH (1.81 g, 19 mmol) in THF/H2O (5.0 mL/7.5 mL) to give 26 as an off-white solid 
(165 mg, 70%); Rf 0.24 (10% MeOH in EtOAc); mp 210-211 ºC; λmax (EtOH)/nm 284, 234; IR 
υmax/cm-1 3319, 2980, 1668, 1630; 1H NMR (300 MHz, DMSO-d6) δ 7.05 (1H, s, H-pyrrole), 7.33-
7.37 (2H, m, 2 × H-Ar), 7.52 (1H, s, H-pyrrole), 7.58-7.66 (1H, m, H-Ar), 12.61 (1H, s br, NH), 
12.98 (1H, s br, COOH); 13C NMR (75 MHz, DMSO-d6) δ 114.6, 119.4, 124.7, 124.9, 125.2, 
125.6, 129.9, 130.0, 146.7, 149.8, 161.4, 184.6; 19F NMR (470 MHz, DMSO-d6) δ -137.7, -141.4; 
MS (ES-) m/z 250.0 [M-H]-. 
4-(2,6-Difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (27) Prepared according to general 
procedure B using methyl 4-(2,6-difluorobenzoyl)-1H-pyrrole-2-carboxylate 15 (160 mg, 0.7 
mmol), LiOH (1.29 g, 13.5 mmol) in THF/H2O (4.5 mL/6.8 mL) to give 27 as a pale orange solid 
(110 mg, 65%); Rf 0.25 (10% MeOH in EtOAc); mp 197-199 ºC; λmax (EtOH)/nm 392, 281, 232; 
IR υmax/cm-1 3352, 2921, 1689, 1623; 1H NMR (500 MHz, DMSO-d6) δ 6.99 (1H, s, H-pyrrole), 
7.23-7.27 (2H, m, 2 × H-Ar), 7.50 (1H, s, H-pyrrole), 7.61-7.64 (1H, m, H-Ar), 12.70 (1H, s br, 
NH), 12.96 (1H, s br, COOH); 13C NMR (125 MHz, DMSO-d6) δ 112.2, 114.0, 117.6, 125.8, 
126.1, 129.6, 132.2, 158.6, 161.4, 181.6; 19F NMR (470 MHz, DMSO-d6) δ -114.2; HRMS calcd. 
for C12H8NF2O3 [M+H]
+ 252.0467, found 252.0470.    
4-(2,6-Dichlorobenzoyl)-1H-pyrrole-2-carboxylic acid (28) Prepared according to general 
procedure B using methyl 4-(2,6-dichlorobenzoyl)-1H-pyrrole-2-carboxylate 16 (300 mg, 1.00 
mmol), LiOH (1.92 g, 20.0 mmol) in THF/H2O (7.0 mL/10.5 mL) to give 28 as an off-white solid 
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(265 mg, 93%); Rf 0.06 (10% MeOH in EtOAc); mp 268-270 ºC; λmax (EtOH)/nm 279, 233; IR 
υmax/cm-1 3286, 1703, 1641; 1H NMR (300 MHz, DMSO-d6) δ 6.92 (1H, s, H-pyrrole), 7.41 (1H, 
s, H-pyrrole), 7.49-7.53 (1H, m, H-Ar), 7.58-7.59 (2H, m, 2 × H-Ar), 12.68 (1H, s br, NH), 12.91 
(1H, s, COOH); 13C NMR (75 MHz, DMSO-d6) δ 114.2, 124.5, 125.8, 128.4, 129.5, 130.5, 131.4, 
138.1, 161.3, 185.6; MS (ES+) m/z 284.0 [M+H]+.  
4-(2-Chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (29) Prepared according to general 
procedure B using methyl 4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylate 17 (4.00 g, 
14.20 mmol), LiOH (6.81 g, 284.00 mmol) in THF/H2O (100 mL/150 mL) to give 29 as a white 
solid (3.75 g, 99%); Rf 0.36 (5% MeOH in EtOAc); mp 209-210 °C; λmax (EtOH)/nm 281, 233; IR 
υmax/cm-1 3306, 1638, 1556; 1H NMR (500 MHz, DMSO-d6) δ 6.95 (1H, s, H-3), 7.35-7.40 (1H, 
m, H-5’), 7.44-7.46 (2H, m, H-3’ and H-5), 7.57 (1H, ddd, J = 6.4, 8.4 and 8.6 Hz, H-4’), 12.69 
(1h, s br, NH); 13C NMR (125 MHz, DMSO-d6) δ 114.0, 114.9, 125.2, 125.2, 126.1, 127.8, 129.5, 
130.3, 131.8, 158.5, 161.4, 183.7; 19F NMR (470 MHz, DMSO-d6) δ -114.0; HRMS m/z calcd for 
C12H6
35ClFNO3 [M-H]
- 266.0026, found 266.0019. 
4-(2-Bromo-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (30) Prepared according to general 
procedure B using methyl 4-(2-bromo-6-fluorobenzoyl)-1H-pyrrole-2-carboxylate 18 (1.00 g, 
3.06 mmol), LiOH (1.46 g, 61.12 mmol) in THF/H2O (25 mL/40 mL) to give 30 as a white solid 
(949 mg, 99%); Rf 0.40 (5% MeOH in EtOAc); mp 210-211 °C; λmax (EtOH)/nm 281; IR υmax/cm-
1 3342, 1690, 1648, 1561; 1H NMR (500 MHz, DMSO-d6) δ 6.94 (1H, s, H-3), 7.39-7.43 (2H, m, 
H-5 and H-5’), 7.50 (1H, ddd, J = 6.3, 8.4 and 8.4 Hz, H-4’), 7.59 (1H, d, J = 8.4 Hz, H-Ar), 12.69 
(1H, s br, NH), 12.81 (1H, s br, COOH);  13C NMR (125 MHz, DMSO-d6) δ 114.1, 115.3, 118.9, 
124.9, 126.0, 128.8, 129.6, 129.8, 132.1, 158.3, 161.3, 184.6; 19F NMR (470 MHz, DMSO-d6) δ -
113.8; HRMS m/z calcd for C12H6
79BrFNO3 [M-H]
- 309.9521, found 309.9516. 
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4-(Benzoyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide (31) Prepared according to 
general procedure C using 4-(benzoyl)-1H-pyrrole-2-carboxylic acid 19 (100 mg, 0.47 mmol), 
carbonyl diimidazole (151 mg, 0.93 mmol) and 3-picolylamine (0.12 mL, 1.08 mmol) in THF (4 
mL). Purification via MPLC (silica; 5-10% MeOH in EtOAc) gave 31 as a white solid (56 mg, 
40%); mp 234-235 ºC; λmax (EtOH)/nm 289, 242; IR υmax/cm-1 3321, 3202, 3105, 1612, 1565, 
1535; 1H NMR (300 MHz, DMSO-d6) δ 4.47 (2H, d, J = 5.4 Hz, CH2), 7.30 (2H, d, J = 4.5 Hz, 2 
x H-Ar), 7.40 (s, 1H, H-pyrrole), 7.44 (1H, s, H-pyrrole), 7.48-7.67 (3H, m, 3 x H-Ar), 7.79 (2H, 
d, J = 7.8 Hz, 2 x H-Ar), 8.51 (2H, d, J = 4.2 Hz, 2 x H-Ar), 8.97 (1H, m, NH), 12.35 (1H, s, NH); 
13C NMR (75 MHz, DMSO-d6) δ 40.9 (CH2), 111.2 (CH-pyrrole), 121.8 (2 x CH-Ar), 123.8 (C), 
127.2 (C), 128.0 (5 x CH-Ar), 131.1 (CH-pyrrole), 139.0 (C-Ar), 148.1 (C-Ar), 149.1 (2 x CH-
Ar), 160.0 (CON), 188.9 (CO); HRMS (ES+) calcd for C18H15N3O2 [M+H]
+ 306.1237, found 
306.1242; Anal. calcd for C18H15N3O2: C, 70.81%, H, 4.95%, N, 13.76%, found: C, 70.89%, H, 
4.61%, N, 13.67%. 
4-(2-Fluorobenzoyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide (32) Prepared 
according to general procedure C using 4-(2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid 20 (100 
mg, 0.43 mmol), carbonyl diimidazole (140 mg, 0.86 mmol) and 4-picolylamine (0.11 mL, 1.07 
mmol) in THF (4 mL). Purification via MPLC (silica; 2-10% MeOH in EtOAc) gave 32 as a white 
solid (94 mg, 68%); mp 226-227 ºC; λmax (EtOH)/nm 287, 238; IR υmax/cm-1 3370, 3173, 1605, 
1568, 1532, 1480; 1H NMR (300 MHz, DMSO-d6) δ 4.46 (2H, d, J = 5.7 Hz, CH2), 7.23-7.42 (6H, 
m, 2 x H-pyrrole and 4 x H-Ar), 7.49-7.65 (2H, m, 2 x H-Ar), 8.50 (2H, d, J = 4.5 Hz, 2 x H-Ar), 
8.97 (1H, m, NH), 12.40 (1H, s, NH); 13C NMR (75 MHz, DMSO-d6) δ 40.9 (CH2), 110.5 (CH-
pyrrole), 115.7 (d, JC-F = 21.5 Hz, CH-Ar), 121.8 (2 x CH-Ar), 124.0 (d, JC-F = 3.2 Hz, CH-Ar), 
124.9 (C), 127.6 (C and CH-pyrrole), 128.1 (d, JC-F = 15.9 Hz, C), 129.2 (d, JC-F = 3.1 Hz, CH-
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Ar), 131.9 (d, JC-F = 8.2 Hz, CH-Ar), 148.1 (C-Ar), 149.1 (2 x CH-Ar), 158.4 (d, JC-F = 247.1 Hz, 
C-F), 159.9 (CON), 185.9 (CO); HRMS (ES+) calcd for C18H14FN3O2 [M+H]
+ 324.1143, found 
324.1146; Anal. calcd for C18H14FN3O2: C, 66.87%, H, 4.36%, N, 13.00%; found: C, 66.81%, H, 
4.34%, N, 12.99%. 
4-(3-Fluorobenzoyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide (33) Prepared 
according to general procedure C using 4-(3-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid 21 (100 
mg, 0.43 mmol), carbonyl diimidazole (140 mg, 0.86 mmol) and 4-picolylamine (0.11 mL, 1.08 
mmol) in THF (3 mL). Purification via MPLC (silica; 0-5% MeOH in EtOAc) and recrystallisation 
from EtOAc/petrol gave 33 as a white solid (105 mg, 76%); Rf 0.19 (EtOAc); mp 195-197 ºC; λmax 
(EtOH)/nm 290, 141; IR υmax/cm-1 3198, 1610, 1573; 1H NMR (500 MHz, DMSO-d6) δ 4.48 (2H, 
d, J = 6.0 Hz, NHCH2), 7.30 (2H, d, J = 6.0 Hz, 2 × H-pyridyl), 7.41 (1H, d, J = 1.5 Hz, H-pyrrole), 
7.47-7.50 (2H, m, H-Ar and H-pyrrole), 7.53-7.56 (1H, m, H-Ar), 7.59 (1H, dd, J = 5.5 and 7.9 
Hz, H-Ar), 7.63-7.65 (2H, m, 2 × H-Ar), 8.51 (2H, d, J = 6.0 Hz, 2 × H-pyridyl), 8.99 (1H, t, J = 
6.0 Hz, NHCH2), 12.43 (1H, s, NH); 
13C NMR (75 MHz, DMSO-d6) δ 41.9, 112.1, 115.1, 115.4, 
118.6, 118.9, 123.7, 124.2, 124.9, 127.9, 128.4, 131.0, 141.9, 146.6, 160.8, 162.3, 188.2; 19F NMR 
(470 MHz, DMSO-d6) δ -112.3; HRMS calcd. for C18H15FN3O2 [M+H]+ 324.1143, found 
324.1146. 
4-(4-Fluorobenzoyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide (34) Prepared 
according to general procedure C using 4-(4-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid 22 (50 
mg, 0.2 mmol), carbonyl diimidazole (70 mg, 0.42 mmol) and 4-picolylamine (0.05 mL, 0.53 
mmol) in THF (3 mL). Purification via MPLC (silica; 0-5% MeOH in  EtOAc) gave 34 as a white 
solid (50 mg, 70%); Rf 0.06 (EtOAc); mp 236-237 ºC; λmax (EtOH)/nm 290, 241; IR υmax/cm-1 
3328, 3236, 1645, 1600; 1H NMR (500 MHz, DMSO-d6) δ 4.48 (2H, d, J = 6.0 Hz, NHCH2), 7.30 
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(2H, d, J = 6.0 Hz, 2 × H-pyridyl), 7.35-7.39 (2H, m, 2 × H-Ar), 7.40 (1H, d, J = 1.3 Hz, H-
pyrrole), 7.47 (1H, d, J = 1.3 Hz, H-pyrrole), 7.87-7.89 (2H, m, 2 × H-Ar), 8.51 (2H, d, J = 6.0 
Hz, 2 × H-pyridyl), 8.98 (1H, t, J = 6.0 Hz, NHCH2), 12.48 (1H, s br, NH); 
13C NMR (125 MHz, 
DMSO-d6) δ 41.1, 111.5, 115.3, 115.5, 122.1, 123.9, 127.5, 127.9, 131.2, 131.3, 135.6, 148.5, 149 
5, 160.3, 164.1, 187.9; 19F NMR (470 MHz, DMSO-d6) δ -108.0; HRMS calcd. for C18H15N3FO2 
[M+H]+ 324.1143, found 324.1140.  
4-(2-Chlorobenzoyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide (35) Prepared 
according to general procedure C using 4-(2-chlorobenzoyl)-1H-pyrrole-2-carboxylic acid 23 (100 
mg, 0.40 mmol), carbonyl diimidazole (130 mg, 0.80 mmol) and 4-picolylamine (0.10 mL, 1.00 
mmol) in THF (3 mL). Purification via MPLC (silica; 0-5% MeOH in EtOAc) and recrystallisation 
from EtOAc/petrol gave 35 as a white solid (125 mg, 92%); Rf 0.29 (EtOAc); mp 208-210 ºC; λmax 
(EtOH)/nm 285, 237; IR υmax/cm-1 3174, 1616, 1568; 1H NMR (500 MHz, DMSO-d6) δ 4.45 (2H, 
d, J = 6.0 Hz, NHCH2), 7.23 (1H, s, H-pyrrole), 7.25 (1H, s, H-pyrrole), 7.28 (1H, d, J = 6.0 Hz, 
2 × H-pyridyl), 7.46-7.49 (2H, m, 2 × H-Ar), 7.51-7.55 (1H, m, H-Ar), 7.57 (1H, d, J = 8.0 Hz, H-
Ar), 8.51 (2H, d, J = 6.0 Hz, 2 × H-pyridyl), 8.98 (1H, t, J = 6.0 Hz, NHCH2), 12.42 (1H, s br, 
NH); 13C NMR (75 MHz, DMSO-d6) δ 41.1, 110.7, 122.1, 124.9, 127.1, 128.0, 128.4, 128.5, 129.4, 
129.8, 131.0, 139.5, 148.5, 149.5, 160.2, 188.4; HRMS calcd. for C18H15N3O2
35Cl [M+H]+ 
340.0847, found 340.0842. 
4-(3-Chlorobenzoyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide (36) Prepared 
according to general procedure C using 4-(3-chlorobenzoyl)-1H-pyrrole-2-carboxylic acid 24 (100 
mg, 0.40 mmol), carbonyl diimidazole (130 mg, 0.80 mmol) and 4-picolylamine (0.10 mL, 1.0 
mmol) in THF (3 mL). Purification via MPLC (silica; 0-80% EtOAc in petroleum ether) gave 36 
as a white solid (125 mg, 90%); Rf 0.17 (10% MeOH in EtOAc); mp 192-194 ºC; λmax (EtOH)/nm 
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299, 243; IR υmax/cm-1 3196, 1608, 1569; 1H NMR (500 MHz, DMSO-d6) δ 4.49 (2H, d, J = 6.0 
Hz, NHCH2), 7.31 (2H, d, J = 6.0 Hz, 2 × H-pyridyl), 7.41 (1H, s, H-pyrrole), 7.50 (1H, s, H-
pyrrole), 7.58 (1H, dd, J = 7.8 and 8.0 Hz, H-Ar), 7.69-7.71 (1H, m, H-Ar), 7.74-7.76 (2H, m, 2 × 
H-Ar), 8.52 (2H, d, J = 6.0 Hz, 2 × H-pyridyl), 9.01 (1H, t, J = 6.0 Hz, NHCH2), 12.45 (1H, s br, 
NH); 13C NMR (75 MHz, DMSO-d6) δ 41.1, 111.4, 122.1, 123.6, 127.2, 127.7, 127.9, 128.2, 130.5, 
131.4, 133.3, 141.1, 148.5, 149.5, 160.3, 187.8; HRMS calcd. for C18H15
35ClN3O2 [M+H]
+ 
340.0847, found 340.0851.  
4-(4-Chlorobenzoyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide (37) Prepared 
according to general procedure C using 4-(4-chlorobenzoyl)-1H-pyrrole-2-carboxylic acid 25 (100 
mg, 0.40 mmol), carbonyl diimidazole (130 mg, 0.80 mmol) and 4-picolylamine (0.10 mL, 1.00 
mmol) in THF (3 mL). Purification via MPLC (silica; 0-5% MeOH in EtOAc) and recrystallisation 
from EtOAc/petrol gave 37 as a white solid (110 mg, 80%); Rf 0.13 (EtOAc); mp 213-215 ºC; λmax 
(EtOH)/nm 290, 246; IR υmax/cm-1  3350, 1628, 1568; 1H NMR (500 MHz, DMSO-d6) δ 4.48 (2H, 
d, J = 6.0 Hz, NHCH2), 7.30 (2H, d, J = 6.0 Hz, 2 × H-pyridyl), 7.39 (1H, d, J = 1.5 Hz, H-pyrrole), 
7.48 (1H, d, J = 1.5 Hz, H-pyrrole), 7.60 (2H, d, J = 7.5 Hz, 2 × H-Ar), 7.81 (2H, d, J = 7.5 Hz, 2 
× H-Ar), 8.51 (2H, d, J = 6.0 Hz, 2 × H-pyridyl), 8.98 (1H, t, J = 6.0 Hz, CH2NH); 
13C NMR (75 
MHz, DMSO-d6) δ 41.1, 111.4, 122.1, 123.8, 127.6, 128.0, 128.6, 130.4, 136.5, 137.8, 148.5, 
149.5, 160.3, 188.1; HRMS calcd. for C18H15N3O2
35Cl [M+H]+ 340.0847, found 340.0849.  
4-(2,3-Difluorobenzoyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide (38) Prepared 
according to general procedure C using 4-(2,3-difluorobenzoyl)-1H-pyrrole-2-carboxylic acid 26 
(100 mg, 0.40 mmol), carbonyl diimidazole (130 mg, 0.80 mmol) and 4-picolylamine (0.10 mL, 
1.0 mmol) in THF (3 mL). Purification via MPLC (silica; 0-5% MeOH in EtOAc) and 
recrystallisation from EtOAc/petrol gave 38 as a white solid (110 mg, 81%); Rf 0.20 (EtOAc); mp 
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244-246 ºC; λmax (EtOH)/nm 287, 238; IR υmax/cm-1  3121, 1627, 1568; 1H NMR (300 MHz, 
DMSO-d6) δ 4.48 (2H, d, J = 6.0 Hz, NHCH2), 7.30 (2H, d, J = 6.0 Hz, 2 × H-pyridyl), 7.34 (1H, 
s, H-pyrrole), 7.35-7.39 (2H, m, 2 × H-Ar), 7.44 (1H, s, H-pyrrole), 7.60-7.66 (1H, m, H-Ar), 8.51 
(2H, d, J = 6.0 Hz, 2 × H-pyridyl), 8.97 (1H, t, J = 6.0 Hz, NHCH2), 12.47 (1H, s br, NH); 
13C 
NMR (75 MHz, DMSO-d6) δ 41.7, 111.2, 119.5, 122.6, 125.0, 125.3, 125.5, 128.6, 128.9, 130.9, 
146.9, 148.8, 148.9, 150.4, 160.6, 185.2; 19F NMR (470 MHz, DMSO-d6) δ -137.8, -141.5; HRMS 
calcd. for C18H14F2N3O2 [M+H]+ 342.1049, found 342.1050. 
4-(2,6-Difluorobenzoyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide (39) Prepared 
according to general procedure C using 4-(2,6-difluorobenzoyl)-1H-pyrrole-2-carboxylic acid 27 
(50 mg, 0.2 mmol), carbonyl diimidazole (65 mg, 0.4 mmol) and 4-picolylamine (0.05 mL, 0.5 
mmol) in THF (3 mL). Purification via MPLC (silica; 0-95% EtOAc in petroleum ether) and 
recrystallisation from EtOAc/petrol gave 39 as a white solid (50 mg, 73%); Rf 0.19 (EtOAc); mp 
226-227 ºC; λmax (EtOH)/nm 284, 236; IR υmax/cm-1 3265, 2921, 1624; 1H NMR (500 MHz, 
DMSO-d6) δ 4.46 (2H, d, J = 6.0 Hz, NHCH2), 7.24-7.27 (2H, m, 2 × H-Ar), 7.29-7.30 (3H, m, 
H-pyrrole, 2 × H-pyridyl), 7.43 (1H, s, H-pyrrole), 7.58-7.64 (1H, m, H-Ar), 8.51 (2H, d, J = 6.0 
Hz, 2 × H-pyridyl), 8.97 (1H, t, J = 6.0 Hz, NHCH2), 12.53 (1H, s br, NH); 
13C NMR (125 MHz, 
DMSO-d6) δ 41.1, 110.3, 112.3, 117.9, 122.1, 125.7, 128.3, 128.5, 132.1, 148.4, 149.5, 158.6, 
160.1, 181.8; 19F NMR (470 MHz, DMSO-d6) δ -114.3; HRMS calcd. for C18H14F2N3O2 [M+H]+ 
342.1049, found 342.1048.  
4-(2,6-Dichlorobenzoyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide (40) Prepared 
according to general procedure C using 4-(2,6-dichlorobenzoyl)-1H-pyrrole-2-carboxylic acid 28 
(100 mg, 0.35 mmol), carbonyl diimidazole (115 mg, 0.70 mmol) and 4-picolylamine (0.09 mL, 
0.88 mmol) in THF (3 mL). Purification via MPLC (silica; 0-5% MeOH in EtOAc) and 
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recrystallisation from EtOAc/petrol gave 40 as a white solid (110 mg, 84%); Rf 0.31 (EtOAc); mp 
143-145 ºC; λmax (EtOH)/nm 285, 237, 206; IR υmax/cm-1  1628, 1559; 1H NMR (500 MHz, DMSO-
d6) δ 4.45 (2H, d, J = 6.0 Hz, NHCH2), 7.22 (1H, s, H-pyrrole), 7.29 (2H, d, J = 6.0 Hz, 2 × H-
pyridyl), 7.32 (1H, s, H-pyrrole), 7.52 (1H, dd, J = 7.0 and 7.1 Hz, H-Ar), 7.58-7.60 (2H, m, 2 × 
H-Ar), 8.50 (2H, d,  J = 6.0 Hz, 2 × H-pyridyl), 8.98 (1H, t, J = 6.0 Hz, NHCH2), 12.49 (1H, s br, 
NH); 13C NMR (125 MHz, DMSO-d6) δ 41.1, 110.2, 122.1, 124.3, 128.3, 128.4, 128.5, 130.5, 
131.3, 138.3, 148.4, 149.5, 160.1, 185.8; HRMS calcd. for C18H14
35Cl2N3O2 [M+H]
+ 374.0458, 
found 374.0462.  
4-(2,6-Difluorobenzoyl)-N-(pyridin-4-yl)-1H-pyrrole-2-carboxamide (41) Prepared according 
to general procedure C using 4-(2,6-difluorobenzoyl)-1H-pyrrole-2-carboxylic acid 27 (100 mg, 
0.40 mmol), carbonyl diimdazole (129 mg, 0.80 mmol), 4-aminopyridine (94 mg, 1.00 mmol) and 
THF (4 mL). Purification via MPLC (silica; 2-30% MeOH in EtOAc) gave 41 as a white solid (50 
mg, 38%); Rf = 0.52 (5% MeOH in EtOAc); mp degraded >290 °C; λmax (EtOH)/nm: 292, 271; 
υmax/cm-1: 3655, 3368, 2585, 2235, 2019, 1588, 1506; 1H NMR (500 MHz, DMSO-d6) δ 7.26-7.30 
(2H, m, H-3’ and H-5’); 7.57 (1H, s, H-3), 7.58 (1H, s, H-5),  7.64 (1H, dddd, J = 6.7, 6.8, 8.4 and  
8.5 Hz, H-4’), 7.75 (2H, d, J = 6.4 Hz, CH-pyridine), 8.47 (2H, d, J = 6.4 Hz, CH-N-pyridine), 
10.36 (1H, s, CONH), 12.78 (1H, br s, NH); 13C NMR (125 MHz, MeOD) δ 112.1 (C-Ar), 112.2 
(C-Ar), 112.4 (C-Ar), 113.7 (C-Ar), 122.0 (C-3), 125.9 (C-2 and C-5), 129.9 (C-4), 145.6 (C-Ar), 
150.3 (C-Ar), 157.7 (C-Ar), 159.6 (C-Ar) 159.7 (CONH), 181.8 (CO); 19F NMR (470 MHz, 
MeOD) δ -114.1; MS (ES+) m/z 328.10 [M+H]+; HRMS m/z calcd for C17H12F2N3O2 [M+H]+ 
328.0890, found 328.0890. 
4-(2,6-Difluorobenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide (42) Prepared according 
to general procedure C using 4-(2,6-difluorobenzoyl)-1H-pyrrole-2-carboxylic acid 27 (50 mg, 
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0.20 mmol), carbonyldiimidazole (65 mg, 0.40 mmol), 3-aminopyridine (47 mg, 0.50 mmol) and 
THF (2 mL). Purification via MPLC (silica; 0-30% MeOH in EtOAc) 42 as a white solid (23 mg, 
35%); Rf 0.78 (5% MeOH in EtOAc); mp 160-161 °C; λmax (EtOH)/nm 290, 240; IR υmax/cm-1 
3243, 3021, 2437, 1622, 1538; 1H NMR (500 MHz, DMSO-d6) δ 7.04-7.07 (2H, m, H-3’ and H-
5’), 7.15 – 7.17 (1H, m, H-3), 7.30-7.32 (2H, m, CH-pyridine), 7.41 (1H, dddd, J = 6.8, 6.8, 8.5 
and 8.5 Hz, H-4’), 7.90-7.93 (1H, m, H-5), 8.08 (1H, dd, J = 1.5 and 4.7 Hz, CH-pyridine), 8.67 
(1H, d, J = 2.5 Hz CH-N-pyridine), 10.02 (1H, s, CONH), 12.50 (1H, s br, NH); 13C NMR (125 
MHz, MeOD) δ 112.9, 113.1, 122.6, 125.2, 128.0, 129.5, 130.6, 133.2, 136.4, 137.5, 142.4, 145.1, 
160.9, 184.7; 19F NMR (470 MHz, MeOD) δ -115.4; HRMS calcd for C17H12F2N3O2 [M+H]+ 
328.0894, found 328.0895. 
4-(2-Chloro-6-fluorobenzoyl)-N-(pyridin-4-yl)-1H-pyrrole-2-carboxamide (43) Prepared 
according to general procedure D using 4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic 
acid 29 (75 mg, 0.28 mmol), MeCN (1.5 mL), 4-aminopyridine (66 mg, 0.70 mmol) and PCl3 (25 
µL, 0.28 mmol). Purification via MPLC (silica; 0-8% MeOH in DCM) gave 43 as a white solid 
(59 mg, 61%); Rf 0.31 (5% MeOH in DCM); mp degraded >270 °C; λmax (EtOH)/nm 341, 291, 
271; IR υmax/cm-1 3416, 3354, 1682, 1632, 1586, 1552, 1506; 1H NMR (500 MHz, DMSO-d6) δ 
7.40-7.43 (1H, m, H-5’), 7.47-7.48 (1H, m, H-3’), 7.51 (1H, s, H-3), 7.55 (1H, s, H-5), 7.59 (1H, 
ddd, J = 6.2, 8.3 and 8.4 Hz, H-4’), 7.74 (2H, d, J = 6.3 Hz, CH-pyridine), 8.47 (2H, d, J = 6.3 Hz, 
N-CH-pyridine), 10.36 (1H, s, CO-NH), 12.76 (1H, s, NH); 13C NMR (125 MHz, DMSO-d6) δ 
112.1, 113.7, 115.0, 125.3, 125.9, 127.9, 128.0, 129.8, 130.4, 131.9, 145.6, 150.3, 158.6, 159.0, 
183.9; HRMS calcd for C17H11
35ClFN3O2 [M+H]
+ 344.0597, found 344.0592. 
4-(2-Chloro-6-fluorobenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide (44) Prepared 
according to general procedure D using 4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic 
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acid 29 (75 mg, 0.28 mmol), MeCN (1.5 mL), 3-aminopyridine (66 mg, 0.70 mmol) and PCl3 (25 
µL, 0.28 mmol). Purification via MPLC (silica; 0-8% MeOH in DCM) gave 44 as a white solid 
(62 mg, 64%); Rf 0.29 (5% MeOH in DCM); mp degraded >260 °C; λmax (EtOH)/nm 350, 248; IR 
υmax/cm-1 3122, 2963, 1635, 1602, 1535; 1H NMR (500 MHz, DMSO-d6) δ 7.38-7.43 (2H, m, H-
3 and H-5’), 7.47-7.50 (3H, m, H-5, H-3’ and CH-pyridine), 7.59 (1H, ddd, J = 6.2, 8.3 and 8.4 
Hz, H-4’), 8.14 (1H, ddd, J = 1.5, 2.5 and 8.3 Hz, CH-pyridine), 8.30 (1H, dd, J = 1.5 and 4.7 Hz, 
N-CH-pyridine), 8.89 (1H, d, J = 2.5 Hz, N-CH-pyridine), 10.24 (1H, s, CO-NH), 12.71 (1H, s, 
NH); 13C NMR (125 MHz, DMSO-d6) δ 111.6, 115.0, 123.5, 125.3, 125.9, 127.0, 128.0, 128.2, 
129.3, 130.4, 131.8, 135.5, 141.6, 144.4, 158.6, 158.7, 183.9; HRMS calcd for C17H11
35ClFN3O2 
[M+H]+ 344.0597, found 344.0592. 
4-(2-Bromo-6-fluorobenzoyl)-N-(pyridin-4-yl)-1H-pyrrole-2-carboxamide (45) Prepared 
according to general procedure D using 4-(2-bromo-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic 
acid 30 (50 mg, 0.16 mmol), MeCN (1 mL), 4-aminopyridine (38 mg, 0.40 mmol) and PCl3 (14 
µL, 0.16 mmol). Purification via MPLC (silica; 0-8% MeOH in DCM) gave 45 as a white solid 
(52 mg, 84%); Rf 0.32 (5% MeOH in DCM); mp degraded >150 °C; λmax (EtOH)/nm 291, 270; IR 
υmax/cm-1 3344, 3112, 2958, 1627, 1591, 1557, 1506; 1H NMR (500 MHz, DMSO-d6) δ 7.42-7.46 
(1H, m, H-5’), 7.49-7.54 (3H, m, H-3, H-4’ and H-5), 7.61-7.62 (1H, m, H-3’), 7.73 (2H, d, J = 
6.4 Hz, CH-pyridine), 8.46 (2H, d, J = 6.4 Hz, N-CH-pyridine), 10.35 (1H, s, CONH), 12.74 (1H, 
s, NH); 13C NMR (125 MHz, DMSO-d6) δ 112.1, 113.7, 115.4, 119.0, 125.0, 128.0, 128.9, 129.8, 
132.2, 145.6, 150.3, 158.5, 159.0, 184.9; HRMS calcd for C17H11
79BrFN3O2 [M+H]
+ 388.0091, 
found 388.0088. 
4-(2-Bromo-6-fluorobenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide (46) Prepared 
according to general procedure D using 4-(2-bromo-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic 
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acid 30 (50 mg, 0.16 mmol), MeCN (1 mL), 3-aminopyridine (38 mg, 0.40 mmol) and PCl3 (14 
µL, 0.16 mmol). Purification via MPLC (silica; 0-8% MeOH in DCM) gave 46 as a white solid 
(47 mg, 76%); Rf 0.31 (5% MeOH in DCM); mp 138-140 °C; λmax (EtOH)/nm 288; IR υmax/cm-1 
3127, 2960, 1635, 1599, 1534; 1H NMR (500 MHz, DMSO-d6) δ 7.39 (1H, dd, J = 4.7 and 8.4 Hz, 
CH-pyridine), 7.42-7.48 (3H, m, H-3, H-5’ and H-5), 7.52 (1H, ddd, J = 6.2, 8.3 and 8.4 Hz, H-
4’), 7.61-7.63 (1H, m, H-3’), 8.14 (1H, ddd, J = 1.5, 2.5 and 8.4 Hz, CH-pyridine), 8.30 (1H, dd, 
J = 1.5 and 4.7 Hz, N-CH-pyridine), 8.89 (1H, d, J = 2.5 Hz, N-CH-pyridine), 10.24 (1H, s, 
CONH), 12.70 (1H, s, NH); 13C NMR (125 MHz, DMSO-d6) δ 111.7, 115.4, 119.0, 123.6, 124.9, 
127.0, 128.8, 129.4, 130.0, 132.1, 135.5, 141.6, 144.4, 158.5, 158.7, 184.9; HRMS calcd for 
C17H11
79BrFN3O2 [M+H]
+ 388.0091, found 388.0090. 
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